table 14.3.1.1.1 summary of adverse events by enrollment ......table 14.3.1.3 adverse events by...
TRANSCRIPT
![Page 1: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/1.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.1.1.1 Summary of Adverse Events by Enrollment Group
Safety Population: IC1
1
30-59 ml/min per 1.73m >60 ml/min per 1.73m
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Number of Events/Participants
Number of Adverse Events 1 0 3 5 6 15
Participants with at least one AE
1 (33.3%) 0 2 (66.7%) 2 (40.0%) 2 (66.7%) 7 (46.7%)
Number of SAEs 0 0 0 1 0 1
Participants with at least one SAE
0 0 0 1 (20.0%) 0 1 (6.7%)
Severity (All AEs)
Mild 1 0 3 4 4 12
Moderate 0 0 0 1 2 3
Highest Severity Per Participant
Mild 1 (33.3%) 0 2 (66.7%) 1 (20.0%) 0 4 (26.7%)
Moderate 0 0 0 1 (20.0%) 2 (66.7%) 3 (20.0%)
Relationship (All AEs)
Not related 1 0 1 3 5 10
Related 0 0 2 2 1 5
Strongest Relationship Per Participant
Not related 1 (33.3%) 0 1 (33.3%) 1 (20.0%) 1 (33.3%) 4 (26.7%)
Related 0 0 1 (33.3%) 1 (20.0%) 1 (33.3%) 3 (20.0%)
Severity (All SAEs)
![Page 2: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/2.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.1.1.1 Summary of Adverse Events by Enrollment Group
Safety Population: IC1
2
30-59 ml/min per 1.73m >60 ml/min per 1.73m
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Mild 0 0 0 1 0 1
Relationship (All SAEs)
Not related 0 0 0 1 0 1
![Page 3: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/3.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.1.1.2 Summary of Adverse Events by Enrollment Group
Safety Population: IC2
1
30-59 ml/min per 1.73m >60 ml/min per 1.73m
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Number of Events/Participants
Number of Adverse Events 1 6 4 1 12
Participants with at least one AE 1 (50.0%) 1 (50.0%) 2 (40.0%) 1 (50.0%) 5 (45.5%)
Severity (All AEs)
Mild 1 5 4 0 10
Moderate 0 1 0 1 2
Highest Severity Per Participant
Mild 1 (50.0%) 0 2 (40.0%) 0 3 (27.3%)
Moderate 0 1 (50.0%) 0 1 (50.0%) 2 (18.2%)
Relationship (All AEs)
Not related 1 6 4 1 12
Strongest Relationship Per Participant
Not related 1 (50.0%) 1 (50.0%) 2 (40.0%) 1 (50.0%) 5 (45.5%)
![Page 4: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/4.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.1.2.1 Adverse Events by System Organ Class, Preferred Term and Enrollment Group
Safety Population
1
30-59 ml/min per 1.73m >60 ml/min per 1.73m
0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=3) 0.1 mg/kg/day
(N=8) 0.2 mg/kg/day
(N=7) 0.4 mg/kg/day
(N=3) Total
(N=26)
System Organ Class Preferred Term
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Blood and lymphatic system disorders
1 (20%) 1 0 0 0 0 0 0 0 0 1 (3.8%) 1
Anaemia 1 (20%) 1 0 0 0 0 0 0 0 0 1 (3.8%) 1
Gastrointestinal disorders
0
0
1 (33.3%)
5
1 (12.5%)
2
2 (28.6%)
2
1 (33.3%)
1
5 (19.2%)
10
Abdominal pain upper 0 0 1 (33.3%) 2 1 (12.5%) 1 0 0 0 0 2 (7.7%) 3
Diarrhoea 0 0 1 (33.3%) 1 0 0 1 (14.3%) 1 0 0 2 (7.7%) 2
Nausea 0 0 0 0 1 (12.5%) 1 1 (14.3%) 1 0 0 2 (7.7%) 2
Retching 0 0 1 (33.3%) 2 0 0 0 0 0 0 1 (3.8%) 2
Vomiting 0 0 0 0 0 0 0 0 1 (33.3%) 1 1 (3.8%) 1
General disorders and administration site conditions
0
0
0
0
2 (25%)
3
0
0
0
0
2 (7.7%)
3
Infusion site extravasation
0 0 0 0 1 (12.5%) 1 0 0 0 0 1 (3.8%) 1
Infusion site pain 0 0 0 0 1 (12.5%) 1 0 0 0 0 1 (3.8%) 1
Infusion site pruritus 0 0 0 0 1 (12.5%) 1 0 0 0 0 1 (3.8%) 1
Infections and infestations
0
0
0
0
0
0
2 (28.6%)
2
0
0
2 (7.7%)
2
Gastroenteritis 0 0 0 0 0 0 1 (14.3%) 1 0 0 1 (3.8%) 1
Otitis externa 0 0 0 0 0 0 1 (14.3%) 1 0 0 1 (3.8%) 1
![Page 5: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/5.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.1.2.1 Adverse Events by System Organ Class, Preferred Term and Enrollment Group
Safety Population
2
30-59 ml/min per 1.73m >60 ml/min per 1.73m
0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=3) 0.1 mg/kg/day
(N=8) 0.2 mg/kg/day
(N=7) 0.4 mg/kg/day
(N=3) Total
(N=26)
System Organ Class Preferred Term
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Injury, poisoning and procedural complications
1 (20%)
1
0
0
0
0
0
0
1 (33.3%)
1
2 (7.7%)
2
Arthropod sting 1 (20%) 1 0 0 0 0 0 0 0 0 1 (3.8%) 1
Upper limb fracture 0 0 0 0 0 0 0 0 1 (33.3%) 1 1 (3.8%) 1
Investigations
0
0
0
0
0
0
0
0
2 (66.7%)
4
2 (7.7%)
4
Glomerular filtration rate decreased
0 0 0 0 0 0 0 0 1 (33.3%) 1 1 (3.8%) 1
Haemoglobin decreased
0 0 0 0 0 0 0 0 1 (33.3%) 1 1 (3.8%) 1
Immunoglobulins abnormal
0 0 0 0 0 0 0 0 1 (33.3%) 1 1 (3.8%) 1
Neutrophil count decreased
0 0 0 0 0 0 0 0 1 (33.3%) 1 1 (3.8%) 1
Nervous system disorders
0
0
1 (33.3%)
1
1 (12.5%)
1
1 (14.3%)
2
0
0
3 (11.5%)
4
Dizziness 0 0 0 0 0 0 1 (14.3%) 2 0 0 1 (3.8%) 2
Headache 0 0 1 (33.3%) 1 1 (12.5%) 1 0 0 0 0 2 (7.7%) 2
Skin and subcutaneous tissue disorders
0
0
0
0
1 (12.5%)
1
0
0
0
0
1 (3.8%)
1
Rash 0 0 0 0 1 (12.5%) 1 0 0 0 0 1 (3.8%) 1
![Page 6: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/6.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group
Safety Population
Note: The percentages are based on the total number of participants in each treatment group or total.
Participants are counted once at each System Organ Class and Preferred Term levels using the highest severity. 1
30-59 ml/min per 1.73m >60 ml/min per 1.73m
System Organ Class Preferred Term Severity
0.1 mg/kg/day (N=5)
0.2 mg/kg/day (N=3)
0.1 mg/kg/day (N=8)
0.2 mg/kg/day (N=7)
0.4 mg/kg/day (N=3)
Total (N=26)
Blood and lymphatic system disorders Mild 1 (20.0%) 0 0 0 0 1 (3.8%)
Anaemia Mild 1 (20.0%) 0 0 0 0 1 (3.8%)
Gastrointestinal disorders Mild 0 0 1 (12.5%) 1 (14.3%) 0 2 (7.7%)
Moderate 0 1 (33.3%) 0 1 (14.3%) 1 (33.3%) 3 (11.5%)
Abdominal pain upper Mild 0 1 (33.3%) 1 (12.5%) 0 0 2 (7.7%)
Diarrhoea Mild 0 1 (33.3%) 0 0 0 1 (3.8%)
Moderate 0 0 0 1 (14.3%) 0 1 (3.8%)
Nausea Mild 0 0 1 (12.5%) 1 (14.3%) 0 2 (7.7%)
Retching Moderate 0 1 (33.3%) 0 0 0 1 (3.8%)
Vomiting Moderate 0 0 0 0 1 (33.3%) 1 (3.8%)
General disorders and administration site conditions Mild 0 0 2 (25.0%) 0 0 2 (7.7%)
Infusion site extravasation Mild 0 0 1 (12.5%) 0 0 1 (3.8%)
Infusion site pain Mild 0 0 1 (12.5%) 0 0 1 (3.8%)
Infusion site pruritus Mild 0 0 1 (12.5%) 0 0 1 (3.8%)
Infections and infestations Mild 0 0 0 2 (28.6%) 0 2 (7.7%)
Gastroenteritis Mild 0 0 0 1 (14.3%) 0 1 (3.8%)
Otitis externa Mild 0 0 0 1 (14.3%) 0 1 (3.8%)
Injury, poisoning and procedural complications Mild 1 (20.0%) 0 0 0 1 (33.3%) 2 (7.7%)
Arthropod sting Mild 1 (20.0%) 0 0 0 0 1 (3.8%)
![Page 7: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/7.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group
Safety Population
Note: The percentages are based on the total number of participants in each treatment group or total.
Participants are counted once at each System Organ Class and Preferred Term levels using the highest severity. 2
30-59 ml/min per 1.73m >60 ml/min per 1.73m
System Organ Class Preferred Term Severity
0.1 mg/kg/day (N=5)
0.2 mg/kg/day (N=3)
0.1 mg/kg/day (N=8)
0.2 mg/kg/day (N=7)
0.4 mg/kg/day (N=3)
Total (N=26)
Upper limb fracture Mild 0 0 0 0 1 (33.3%) 1 (3.8%)
Investigations Mild 0 0 0 0 1 (33.3%) 1 (3.8%)
Moderate 0 0 0 0 1 (33.3%) 1 (3.8%)
Glomerular filtration rate decreased Moderate 0 0 0 0 1 (33.3%) 1 (3.8%)
Haemoglobin decreased Mild 0 0 0 0 1 (33.3%) 1 (3.8%)
Immunoglobulins abnormal Mild 0 0 0 0 1 (33.3%) 1 (3.8%)
Neutrophil count decreased Mild 0 0 0 0 1 (33.3%) 1 (3.8%)
Nervous system disorders Mild 0 1 (33.3%) 1 (12.5%) 0 0 2 (7.7%)
Moderate 0 0 0 1 (14.3%) 0 1 (3.8%)
Dizziness Moderate 0 0 0 1 (14.3%) 0 1 (3.8%)
Headache Mild 0 1 (33.3%) 1 (12.5%) 0 0 2 (7.7%)
Skin and subcutaneous tissue disorders Mild 0 0 1 (12.5%) 0 0 1 (3.8%)
Rash Mild 0 0 1 (12.5%) 0 0 1 (3.8%)
![Page 8: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/8.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.1.4 Adverse Events by System Organ Class, Preferred Term, Relationship to Study Medication and by Enrollment Group
Safety Population
Note: The percentages are based on the total number of participants in each treatment group or total.
Participants are counted once at each System Organ Class and Preferred Term levels using the closest relationship to study drug. 1
30-59 ml/min per 1.73m >60 ml/min per 1.73m
System Organ Class Preferred Term Relationship
0.1 mg/kg/day (N=5)
0.2 mg/kg/day (N=3)
0.1 mg/kg/day (N=8)
0.2 mg/kg/day (N=7)
0.4 mg/kg/day (N=3)
Total (N=26)
Blood and lymphatic system disorders Not related 1 (20.0%) 0 0 0 0 1 (3.8%)
Anaemia Not related 1 (20.0%) 0 0 0 0 1 (3.8%)
Gastrointestinal disorders Not related 0 1 (33.3%) 0 1 (14.3%) 1 (33.3%) 3 (11.5%)
Related 0 0 1 (12.5%) 1 (14.3%) 0 2 (7.7%)
Abdominal pain upper Not related 0 1 (33.3%) 0 0 0 1 (3.8%)
Related 0 0 1 (12.5%) 0 0 1 (3.8%)
Diarrhoea Not related 0 1 (33.3%) 0 1 (14.3%) 0 2 (7.7%)
Nausea Related 0 0 1 (12.5%) 1 (14.3%) 0 2 (7.7%)
Retching Not related 0 1 (33.3%) 0 0 0 1 (3.8%)
Vomiting Not related 0 0 0 0 1 (33.3%) 1 (3.8%)
General disorders and administration site conditions Not related 0 0 2 (25.0%) 0 0 2 (7.7%)
Infusion site extravasation Not related 0 0 1 (12.5%) 0 0 1 (3.8%)
Infusion site pain Not related 0 0 1 (12.5%) 0 0 1 (3.8%)
Infusion site pruritus Not related 0 0 1 (12.5%) 0 0 1 (3.8%)
Infections and infestations Not related 0 0 0 2 (28.6%) 0 2 (7.7%)
Gastroenteritis Not related 0 0 0 1 (14.3%) 0 1 (3.8%)
Otitis externa Not related 0 0 0 1 (14.3%) 0 1 (3.8%)
Injury, poisoning and procedural complications Not related 1 (20.0%) 0 0 0 1 (33.3%) 2 (7.7%)
Arthropod sting Not related 1 (20.0%) 0 0 0 0 1 (3.8%)
![Page 9: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/9.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.1.4 Adverse Events by System Organ Class, Preferred Term, Relationship to Study Medication and by Enrollment Group
Safety Population
Note: The percentages are based on the total number of participants in each treatment group or total.
Participants are counted once at each System Organ Class and Preferred Term levels using the closest relationship to study drug. 2
30-59 ml/min per 1.73m >60 ml/min per 1.73m
System Organ Class Preferred Term Relationship
0.1 mg/kg/day (N=5)
0.2 mg/kg/day (N=3)
0.1 mg/kg/day (N=8)
0.2 mg/kg/day (N=7)
0.4 mg/kg/day (N=3)
Total (N=26)
Upper limb fracture Not related 0 0 0 0 1 (33.3%) 1 (3.8%)
Investigations Not related 0 0 0 0 1 (33.3%) 1 (3.8%)
Related 0 0 0 0 1 (33.3%) 1 (3.8%)
Glomerular filtration rate decreased Related 0 0 0 0 1 (33.3%) 1 (3.8%)
Haemoglobin decreased Not related 0 0 0 0 1 (33.3%) 1 (3.8%)
Immunoglobulins abnormal Not related 0 0 0 0 1 (33.3%) 1 (3.8%)
Neutrophil count decreased Not related 0 0 0 0 1 (33.3%) 1 (3.8%)
Nervous system disorders Not related 0 1 (33.3%) 1 (12.5%) 0 0 2 (7.7%)
Related 0 0 0 1 (14.3%) 0 1 (3.8%)
Dizziness Related 0 0 0 1 (14.3%) 0 1 (3.8%)
Headache Not related 0 1 (33.3%) 1 (12.5%) 0 0 2 (7.7%)
Skin and subcutaneous tissue disorders Not related 0 0 1 (12.5%) 0 0 1 (3.8%)
Rash Not related 0 0 1 (12.5%) 0 0 1 (3.8%)
![Page 10: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/10.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.1.5 Adverse Events Listed by Most Frequent Preferred Term and by Enrollment Group
Safety Population
Events that occurred in 5% or more participants are included.
1
30-59 ml/min per 1.73m >60 ml/min per 1.73m
0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=3) 0.1 mg/kg/day
(N=8) 0.2 mg/kg/day
(N=7) 0.4 mg/kg/day
(N=3) Total
(N=26)
System Organ Class
Preferred Term
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Participants with Event
N (%)
Total Events
N
Gastrointestinal disorders
Abdominal pain upper
0 0 1 (33.3%) 2 1 (12.5%) 1 0 0 0 0 2 (7.7%) 3
Gastrointestinal disorders
Diarrhoea 0 0 1 (33.3%) 1 0 0 1 (14.3%) 1 0 0 2 (7.7%) 2
Nervous system disorders
Headache 0 0 1 (33.3%) 1 1 (12.5%) 1 0 0 0 0 2 (7.7%) 2
Gastrointestinal disorders
Nausea 0 0 0 0 1 (12.5%) 1 1 (14.3%) 1 0 0 2 (7.7%) 2
![Page 11: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/11.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.1.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Hematology
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Hematocrit (%)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 40.5 (3.7) 41.3 41.6 (2.4) 37.2 (3.9) 38.4 (4.5) 39.3 (3.7)
Median (Min, Max) 41.6 (36.4, 43.5) 41.3 (41.3, 41.3) 41.0 (39.6, 44.3) 39.0 (31.0, 40.2) 39.4 (33.4, 42.3) 40.0 (31.0, 44.3)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 38.5 (2.8) 43.7 38.9 (3.1) 35.8 (2.1) 38.6 (6.4) 38.0 (3.4)
Median (Min, Max) 39.1 (35.4, 41.0) 43.7 (43.7, 43.7) 39.8 (35.4, 41.5) 34.8 (33.7, 38.8) 38.6 (34.1, 43.1) 38.0 (33.7, 43.7)
Change from Baseline
N 3 1 3 5 2 14
Mean (SD) -2.0 (0.9) 2.4 -2.7 (4.1) -1.4 (2.6) -2.3 (4.3) -1.7 (2.8)
Median (Min, Max) -2.5 (-2.5, -1.0) 2.4 (2.4, 2.4) -4.5 (-5.6, 1.9) -1.4 (-4.2, 2.7) -2.3 (-5.3, 0.8) -2.0 (-5.6, 2.7)
95% CI for Median 1 (-4.2, 1.9)
Percentage Change
N 3 1 3 5 2 14
Mean (SD) -4.8 (1.8) 5.8 -6.3 (9.8) -3.3 (7.3) -5.8 (10.8) -4.0 (7.1)
Median (Min, Max) -5.8 (-6.0, -2.7) 5.8 (5.8, 5.8) -10.2 (-13.7, 4.8) -3.9 (-10.8, 8.7) -5.8 (-13.5, 1.9) -4.8 (-13.7, 8.7)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 12: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/12.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.1.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Hematology
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Hemoglobin (g/dL)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 13.4 (1.0) 14.5 13.4 (1.0) 12.4 (1.3) 13.2 (1.9) 13.1 (1.3)
Median (Min, Max) 13.8 (12.3, 14.2) 14.5 (14.5, 14.5) 13.6 (12.3, 14.3) 12.9 (10.7, 13.9) 13.2 (11.3, 15.0) 13.2 (10.7, 15.0)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 12.9 (0.8) 15.1 12.3 (1.3) 11.7 (1.0) 12.4 (1.7) 12.4 (1.3)
Median (Min, Max) 13.3 (12.0, 13.3) 15.1 (15.1, 15.1) 12.6 (10.9, 13.4) 11.3 (10.9, 13.1) 12.4 (11.2, 13.6) 12.5 (10.9, 15.1)
Change from Baseline
N 3 1 3 5 2 14
Mean (SD) -0.6 (0.3) 0.6 -1.1 (0.8) -0.7 (0.9) -1.7 (0.4) -0.8 (0.8)
Median (Min, Max) -0.5 (-0.9, -0.3) 0.6 (0.6, 0.6) -1.4 (-1.7, -0.2) -0.6 (-2.0, 0.6) -1.7 (-2.0, -1.4) -0.7 (-2.0, 0.6)
95% CI for Median 1 (-1.4, -0.2)
Percentage Change
N 3 1 3 5 2 14
Mean (SD) -4.1 (2.0) 4.1 -8.3 (5.9) -5.1 (7.5) -12.2 (4.1) -5.9 (6.4)
Median (Min, Max) -3.6 (-6.3, -2.4) 4.1 (4.1, 4.1) -11.4 (-11.9, -1.5) -5.2 (-15.5, 5.6) -12.2 (-15.2, -9.3) -5.5 (-15.5, 5.6)
Participant with at least one newly emergent abnormal finding
0 1 (100.0%) 1 (33.3%) 1 (20.0%) 1 (33.3%) 4 (26.7%)
![Page 13: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/13.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.1.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Hematology
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
3
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Platelets (103/µL)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 247.7 (66.4) 280.0 304.7 (127.6) 279.8 (74.3) 269.7 (67.1) 276.3 (74.4)
Median (Min, Max) 216.0 (203.0, 324.0) 280.0 (280.0, 280.0) 253.0 (211.0, 450.0) 249.0 (206.0, 392.0) 235.0 (227.0, 347.0) 249.0 (203.0, 450.0)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 262.7 (67.6) 250.0 226.7 (62.6) 266.2 (80.2) 258.0 (66.5) 254.6 (62.2)
Median (Min, Max) 267.0 (193.0, 328.0) 250.0 (250.0, 250.0) 213.0 (172.0, 295.0) 262.0 (168.0, 362.0) 258.0 (211.0, 305.0) 256.0 (168.0, 362.0)
Change from Baseline
N 3 1 3 5 2 14
Mean (SD) 15.0 (32.0) -30.0 -78.0 (174.4) -13.6 (85.7) -29.0 (18.4) -24.6 (90.5)
Median (Min, Max) 4.0 (-10.0, 51.0) -30.0 (-30.0, -30.0) 2.0 (-278.0, 42.0) -38.0 (-130.0, 91.0) -29.0 (-42.0, -16.0) -13.0 (-278.0, 91.0)
95% CI for Median 1 (-38.0, 47.0)
Percentage Change
N 3 1 3 5 2 14
Mean (SD) 6.6 (15.0) -10.7 -14.7 (41.5) -2.7 (28.9) -9.6 (3.6) -4.8 (24.9)
Median (Min, Max) 1.2 (-4.9, 23.6) -10.7 (-10.7, -10.7) 1.0 (-61.8, 16.6) -15.3 (-33.2, 38.4) -9.6 (-12.1, -7.0) -6.0 (-61.8, 38.4)
Participant with at least one newly emergent abnormal finding
0 0 0 1 (20.0%) 0 1 (6.7%)
![Page 14: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/14.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.1.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Hematology
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
4
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
WBC (103/µL)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 6.9 (2.9) 5.3 8.7 (3.2) 7.7 (2.4) 6.6 (1.4) 7.3 (2.4)
Median (Min, Max) 8.4 (3.5, 8.7) 5.3 (5.3, 5.3) 7.5 (6.2, 12.3) 7.9 (3.8, 9.9) 6.9 (5.1, 7.9) 7.5 (3.5, 12.3)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 7.7 (1.9) 4.4 9.0 (2.5) 5.7 (1.8) 4.8 (0.9) 6.6 (2.3)
Median (Min, Max) 7.7 (5.8, 9.6) 4.4 (4.4, 4.4) 8.2 (7.0, 11.8) 5.4 (3.9, 8.5) 4.8 (4.2, 5.4) 6.1 (3.9, 11.8)
Change from Baseline
N 3 1 3 5 2 14
Mean (SD) 0.8 (3.5) -0.9 0.3 (0.7) -2.0 (2.1) -1.7 (2.8) -0.8 (2.3)
Median (Min, Max) 1.2 (-2.9, 4.2) -0.9 (-0.9, -0.9) 0.7 (-0.5, 0.8) -1.5 (-5.2, 0.1) -1.7 (-3.7, 0.3) -0.7 (-5.2, 4.2)
95% CI for Median 1 (-2.6, 0.8)
Percentage Change
N 3 1 3 5 2 14
Mean (SD) 33.6 (78.0) -16.2 5.9 (9.2) -22.0 (22.0) -20.1 (37.5) -3.4 (41.6)
Median (Min, Max) 14.3 (-32.9, 119.4) -16.2 (-16.2, -16.2) 8.8 (-4.4, 13.2) -14.7 (-54.5, 2.6) -20.1 (-46.6, 6.5) -7.8 (-54.5, 119.4)
Participant with at least one newly emergent abnormal finding
0 0 0 1 (20.0%) 0 1 (6.7%)
![Page 15: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/15.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.1.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Hematology
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Hematocrit (%)
Pre-dose value
N 2 2 4 2 10
Mean (SD) 33.1 (2.1) 37.2 (7.1) 40.8 (4.3) 33.8 (0.2) 37.1 (4.9)
Median (Min, Max) 33.1 (31.6, 34.5) 37.2 (32.2, 42.2) 41.6 (35.8, 44.4) 33.8 (33.6, 33.9) 35.2 (31.6, 44.4)
Post-dose value
N 2 2 4 1 9
Mean (SD) 30.8 (4.5) 36.8 (10.1) 41.0 (1.3) 31.9 36.8 (6.0)
Median (Min, Max) 30.8 (27.6, 34.0) 36.8 (29.6, 43.9) 40.8 (39.6, 42.6) 31.9 (31.9, 31.9) 39.6 (27.6, 43.9)
Change from Baseline
N 2 2 3 1 8
Mean (SD) -2.3 (2.5) -0.5 (3.0) -1.6 (4.8) -1.7 -1.5 (3.0)
Median (Min, Max) -2.3 (-4.0, -0.5) -0.5 (-2.6, 1.7) -4.0 (-4.8, 3.9) -1.7 (-1.7, -1.7) -2.2 (-4.8, 3.9)
95% CI for Median 1 (-4.0, 3.9)
Percentage Change
N 2 2 3 1 8
Mean (SD) -7.1 (7.9) -2.0 (8.6) -3.3 (11.6) -5.1 -4.1 (7.9)
Median (Min, Max) -7.1 (-12.7, -1.4) -2.0 (-8.1, 4.0) -9.0 (-10.8, 10.1) -5.1 (-5.1, -5.1) -6.6 (-12.7, 10.1)
Participant with at least one newly emergent abnormal finding
0 1 (50.0%) 0 1 (50.0%) 2 (18.2%)
![Page 16: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/16.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.1.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Hematology
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Hemoglobin (g/dL)
Pre-dose value
N 2 2 4 2 10
Mean (SD) 11.1 (0.8) 12.4 (1.8) 13.4 (1.6) 11.2 (0.0) 12.3 (1.6)
Median (Min, Max) 11.1 (10.5, 11.7) 12.4 (11.1, 13.6) 13.8 (11.3, 14.8) 11.2 (11.2, 11.2) 11.5 (10.5, 14.8)
Post-dose value
N 2 2 4 1 9
Mean (SD) 10.2 (1.6) 11.7 (2.6) 13.3 (0.3) 10.8 12.0 (1.8)
Median (Min, Max) 10.2 (9.1, 11.3) 11.7 (9.8, 13.5) 13.3 (13.1, 13.7) 10.8 (10.8, 10.8) 13.1 (9.1, 13.7)
Change from Baseline
N 2 2 3 1 8
Mean (SD) -0.9 (0.7) -0.7 (0.8) -0.9 (1.0) -0.4 -0.8 (0.7)
Median (Min, Max) -0.9 (-1.4, -0.4) -0.7 (-1.3, -0.1) -1.3 (-1.7, 0.2) -0.4 (-0.4, -0.4) -0.9 (-1.7, 0.2)
95% CI for Median 1 (-1.4, 0.2)
Percentage Change
N 2 2 3 1 8
Mean (SD) -8.4 (7.0) -6.2 (7.8) -6.3 (6.9) -3.6 -6.5 (5.6)
Median (Min, Max) -8.4 (-13.3, -3.4) -6.2 (-11.7, -0.7) -9.0 (-11.5, 1.5) -3.6 (-3.6, -3.6) -6.3 (-13.3, 1.5)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 17: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/17.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.1.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Hematology
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
3
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Platelets (103/µL)
Pre-dose value
N 2 2 4 2 10
Mean (SD) 276.5 (53.0) 259.0 (19.8) 327.5 (101.8) 264.0 (19.8) 290.9 (69.9)
Median (Min, Max) 276.5 (239.0, 314.0) 259.0 (245.0, 273.0) 293.5 (247.0, 476.0) 264.0 (250.0, 278.0) 275.5 (239.0, 476.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 223.5 (13.4) 248.0 (4.2) 201.3 (46.0) 244.0 221.3 (35.5)
Median (Min, Max) 223.5 (214.0, 233.0) 248.0 (245.0, 251.0) 211.0 (139.0, 244.0) 244.0 (244.0, 244.0) 233.0 (139.0, 251.0)
Change from Baseline
N 2 2 3 1 8
Mean (SD) -53.0 (39.6) -11.0 (15.6) -56.0 (53.0) -34.0 -41.3 (38.2)
Median (Min, Max) -53.0 (-81.0, -25.0) -11.0 (-22.0, 0.0) -56.0 (-109.0, -3.0) -34.0 (-34.0, -34.0) -29.5 (-109.0, 0.0)
95% CI for Median 1 (-81.0, 0.0)
Percentage Change
N 2 2 3 1 8
Mean (SD) -18.1 (10.8) -4.0 (5.7) -18.9 (17.3) -12.2 -14.2 (12.3)
Median (Min, Max) -18.1 (-25.8, -10.5) -4.0 (-8.1, 0.0) -19.9 (-35.7, -1.2) -12.2 (-12.2, -12.2) -11.4 (-35.7, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 18: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/18.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.1.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Hematology
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
4
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
WBC (103/µL)
Pre-dose value
N 2 2 4 2 10
Mean (SD) 8.9 (0.8) 4.4 (1.3) 7.9 (0.9) 8.8 (0.3) 7.6 (1.9)
Median (Min, Max) 8.9 (8.3, 9.4) 4.4 (3.5, 5.3) 8.2 (6.6, 8.7) 8.8 (8.6, 9.0) 8.3 (3.5, 9.4)
Post-dose value
N 2 2 4 1 9
Mean (SD) 7.3 (1.6) 4.2 (0.7) 6.3 (1.5) 6.3 6.1 (1.6)
Median (Min, Max) 7.3 (6.2, 8.4) 4.2 (3.7, 4.7) 6.6 (4.2, 7.6) 6.3 (6.3, 6.3) 6.2 (3.7, 8.4)
Change from Baseline
N 2 2 3 1 8
Mean (SD) -1.5 (2.3) -0.2 (0.6) -0.7 (1.5) -2.3 -1.0 (1.4)
Median (Min, Max) -1.5 (-3.2, 0.1) -0.2 (-0.6, 0.2) -0.3 (-2.3, 0.6) -2.3 (-2.3, -2.3) -0.5 (-3.2, 0.6)
95% CI for Median 1 (-2.3, 0.6)
Percentage Change
N 2 2 3 1 8
Mean (SD) -16.0 (25.0) -2.4 (11.8) -7.5 (18.8) -27.0 -10.8 (16.8)
Median (Min, Max) -16.0 (-33.6, 1.7) -2.4 (-10.7, 6.0) -4.2 (-27.7, 9.5) -27.0 (-27.0, -27.0) -7.5 (-33.6, 9.5)
Participant with at least one newly emergent abnormal finding
0 1 (50.0%) 0 0 1 (9.1%)
![Page 19: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/19.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
1
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Bands (%)
Pre-dose value
N 0 0 0 0 1 1
Mean (SD) 0.0 0.0
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Post-dose value
N 1 0 2 2 0 5
Mean (SD) 0.0 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 20: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/20.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Basophils (%)
Pre-dose value
N 3 1 3 4 2 13
Mean (SD) 0.1 (0.2) 0.7 0.3 (0.2) 0.2 (0.3) 0.6 (0.4) 0.3 (0.3)
Median (Min, Max) 0.0 (0.0, 0.3) 0.7 (0.7, 0.7) 0.3 (0.1, 0.5) 0.2 (0.0, 0.6) 0.6 (0.3, 0.8) 0.3 (0.0, 0.8)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 0.1 (0.2) 0.0 0.3 (0.6) 0.6 (0.5) 0.5 (0.7) 0.4 (0.5)
Median (Min, Max) 0.0 (0.0, 0.4) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0) 1.0 (0.0, 1.0) 0.5 (0.0, 1.0) 0.0 (0.0, 1.0)
Change from Baseline
N 3 1 3 4 1 12
Mean (SD) 0.0 (0.1) -0.7 0.0 (0.4) 0.3 (0.8) -0.8 -0.0 (0.6)
Median (Min, Max) 0.0 (0.0, 0.1) -0.7 (-0.7, -0.7) -0.1 (-0.3, 0.5) 0.4 (-0.6, 1.0) -0.8 (-0.8, -0.8) -0.1 (-0.8, 1.0)
95% CI for Median 1 (-0.6, 0.5)
Percentage Change
N 1 1 3 2 1 8
Mean (SD) 33.3 -100.0 -33.3 (115.5) -100.0 (0.0) -100.0 -58.3 (79.2)
Median (Min, Max) 33.3 (33.3, 33.3) -100.0 (-100.0, -100.0) -100.0 (-100.0, 100.0) -100.0 (-100.0, -100.0) -100.0 (-100.0, -100.0) -100.0 (-100.0, 100.0)
Participant with at least one newly emergent abnormal finding
0 0 0 1 (20.0%) 0 1 (6.7%)
![Page 21: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/21.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
3
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Blasts (%)
Pre-dose value
N 0 0 0 0 1 1
Mean (SD) 0.0 0.0
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Post-dose value
N 1 0 2 2 0 5
Mean (SD) 0.0 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 22: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/22.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
4
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Eosinophils (%)
Pre-dose value
N 3 1 3 4 3 14
Mean (SD) 1.2 (0.7) 5.2 2.4 (1.7) 1.6 (1.5) 3.1 (1.7) 2.3 (1.6)
Median (Min, Max) 1.0 (0.7, 2.0) 5.2 (5.2, 5.2) 2.1 (0.9, 4.3) 1.7 (0.0, 3.0) 2.2 (2.0, 5.0) 2.1 (0.0, 5.2)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 2.2 (2.4) 3.0 2.0 (1.0) 5.8 (4.5) 5.0 (2.8) 3.9 (3.3)
Median (Min, Max) 1.0 (0.7, 5.0) 3.0 (3.0, 3.0) 2.0 (1.0, 3.0) 6.0 (1.0, 13.0) 5.0 (3.0, 7.0) 3.0 (0.7, 13.0)
Change from Baseline
N 3 1 3 4 2 13
Mean (SD) 1.0 (2.6) -2.2 -0.4 (0.8) 2.4 (1.0) 1.4 (0.8) 0.9 (1.9)
Median (Min, Max) 0.0 (-1.0, 4.0) -2.2 (-2.2, -2.2) -0.1 (-1.3, 0.1) 2.7 (1.0, 3.2) 1.4 (0.8, 2.0) 0.8 (-2.2, 4.0)
95% CI for Median 1 (-1.0, 3.0)
Percentage Change
N 3 1 3 3 2 12
Mean (SD) 116.7 (246.6) -42.3 -8.0 (20.9) 204.8 (169.2) 38.2 (2.6) 81.2 (157.3)
Median (Min, Max) 0.0 (-50.0, 400.0) -42.3 (-42.3, -42.3) -4.8 (-30.2, 11.1) 114.3 (100.0, 400.0) 38.2 (36.4, 40.0) 23.7 (-50.0, 400.0)
Participant with at least one newly emergent abnormal finding
0 0 0 1 (20.0%) 1 (33.3%) 2 (13.3%)
![Page 23: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/23.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
5
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Lymphocytes (%)
Pre-dose value
N 3 1 3 4 3 14
Mean (SD) 19.6 (17.0) 31.8 44.4 (8.3) 31.6 (11.0) 40.1 (25.0) 33.6 (16.2)
Median (Min, Max) 12.8 (7.0, 39.0) 31.8 (31.8, 31.8) 43.1 (36.8, 53.2) 31.2 (21.0, 43.0) 42.6 (14.0, 63.8) 37.9 (7.0, 63.8)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 17.7 (5.5) 24.0 48.0 (4.0) 42.4 (7.8) 53.5 (12.0) 38.6 (14.6)
Median (Min, Max) 18.0 (12.0, 23.0) 24.0 (24.0, 24.0) 48.0 (44.0, 52.0) 46.0 (30.0, 50.0) 53.5 (45.0, 62.0) 44.5 (12.0, 62.0)
Change from Baseline
N 3 1 3 4 2 13
Mean (SD) -1.9 (18.5) -7.8 3.6 (6.6) 8.9 (11.7) 14.6 (23.2) 4.8 (13.8)
Median (Min, Max) -0.8 (-21.0, 16.0) -7.8 (-7.8, -7.8) 0.9 (-1.2, 11.2) 6.8 (-3.0, 25.0) 14.6 (-1.8, 31.0) 0.9 (-21.0, 31.0)
95% CI for Median 1 (-3.0, 16.0)
Percentage Change
N 3 1 3 4 2 13
Mean (SD) 56.2 (151.2) -24.5 10.1 (17.8) 39.6 (55.0) 109.3 (158.6) 42.4 (90.2)
Median (Min, Max) -6.3 (-53.8, 228.6) -24.5 (-24.5, -24.5) 2.1 (-2.3, 30.4) 23.1 (-7.0, 119.0) 109.3 (-2.8, 221.4) 2.1 (-53.8, 228.6)
Participant with at least one newly emergent abnormal finding
3 (100.0%) 1 (100.0%) 2 (66.7%) 0 0 6 (40.0%)
![Page 24: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/24.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
6
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Metamyelocytes (%)
Pre-dose value
N 0 0 0 0 1 1
Mean (SD) 0.0 0.0
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Post-dose value
N 1 0 2 2 0 5
Mean (SD) 0.0 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 25: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/25.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
7
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Monocytes (%)
Pre-dose value
N 3 1 3 4 2 13
Mean (SD) 9.0 (5.6) 5.6 6.1 (1.0) 5.8 (1.7) 8.9 (1.2) 7.1 (2.9)
Median (Min, Max) 8.1 (4.0, 15.0) 5.6 (5.6, 5.6) 5.9 (5.2, 7.2) 5.6 (4.0, 8.0) 8.9 (8.0, 9.7) 5.9 (4.0, 15.0)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 5.6 (1.5) 12.0 6.3 (1.5) 7.6 (2.3) 6.5 (0.7) 7.1 (2.2)
Median (Min, Max) 6.0 (4.0, 6.9) 12.0 (12.0, 12.0) 6.0 (5.0, 8.0) 8.0 (4.0, 10.0) 6.5 (6.0, 7.0) 7.0 (4.0, 12.0)
Change from Baseline
N 3 1 3 4 1 12
Mean (SD) -3.4 (6.8) 6.4 0.2 (2.2) 1.2 (1.1) -1.0 0.1 (4.1)
Median (Min, Max) -1.2 (-11.0, 2.0) 6.4 (6.4, 6.4) 0.8 (-2.2, 2.1) 1.1 (0.0, 2.6) -1.0 (-1.0, -1.0) 0.9 (-11.0, 6.4)
95% CI for Median 1 (-1.2, 2.1)
Percentage Change
N 3 1 3 4 1 12
Mean (SD) -12.7 (61.7) 114.3 6.8 (33.9) 20.3 (20.4) -12.5 13.8 (47.1)
Median (Min, Max) -14.8 (-73.3, 50.0) 114.3 (114.3, 114.3) 15.4 (-30.6, 35.6) 16.6 (0.0, 48.1) -12.5 (-12.5, -12.5) 13.9 (-73.3, 114.3)
Participant with at least one newly emergent abnormal finding
0 0 0 1 (20.0%) 0 1 (6.7%)
![Page 26: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/26.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
8
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Myelocytes (%)
Pre-dose value
N 0 0 0 0 1 1
Mean (SD) 0.0 0.0
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Post-dose value
N 1 0 2 2 0 5
Mean (SD) 0.0 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 27: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/27.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
9
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Neutrophils (%)
Pre-dose value
N 2 1 1 3 2 9
Mean (SD) 61.6 (23.4) 56.3 48.7 64.3 (13.4) 35.2 (14.1) 54.6 (16.9)
Median (Min, Max) 61.6 (45.0, 78.1) 56.3 (56.3, 56.3) 48.7 (48.7, 48.7) 69.8 (49.0, 74.0) 35.2 (25.2, 45.1) 49.0 (25.2, 78.1)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 74.0 (5.6) 62.0 43.3 (5.9) 44.0 (12.1) 34.0 (9.9) 50.1 (16.4)
Median (Min, Max) 73.0 (69.0, 80.0) 62.0 (62.0, 62.0) 41.0 (39.0, 50.0) 47.0 (27.0, 59.0) 34.0 (27.0, 41.0) 48.0 (27.0, 80.0)
Change from Baseline
N 2 1 1 3 1 8
Mean (SD) 15.0 (18.5) 5.7 1.3 -15.6 (8.1) 1.8 -1.0 (15.5)
Median (Min, Max) 15.0 (1.9, 28.0) 5.7 (5.7, 5.7) 1.3 (1.3, 1.3) -11.0 (-25.0, -10.8) 1.8 (1.8, 1.8) 1.6 (-25.0, 28.0)
95% CI for Median 1 (-11.0, 28.0)
Percentage Change
N 2 1 1 3 1 8
Mean (SD) 32.3 (42.3) 10.1 2.7 -23.9 (9.2) 7.1 1.6 (29.0)
Median (Min, Max) 32.3 (2.4, 62.2) 10.1 (10.1, 10.1) 2.7 (2.7, 2.7) -22.5 (-33.8, -15.5) 7.1 (7.1, 7.1) 2.6 (-33.8, 62.2)
Participant with at least one newly emergent abnormal finding
2 (66.7%) 0 0 1 (20.0%) 1 (33.3%) 4 (26.7%)
![Page 28: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/28.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
10
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Nucleated RBC (%)
Pre-dose value
N 0 0 1 0 1 2
Mean (SD) 2.3 0.0 1.2 (1.6)
Median (Min, Max) 2.3 (2.3, 2.3) 0.0 (0.0, 0.0) 1.2 (0.0, 2.3)
Post-dose value
N 1 0 2 2 0 5
Mean (SD) 0.0 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Change from Baseline
N 0 0 1 0 0 1
Mean (SD) -2.3 -2.3
Median (Min, Max) -2.3 (-2.3, -2.3) -2.3 (-2.3, -2.3)
95% CI for Median 1 (., .)
Percentage Change
N 0 0 1 0 0 1
Mean (SD) -100.0 -100.0
Median (Min, Max) -100.0 (-100.0, -100.0) -100.0 (-100.0, -100.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 29: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/29.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
11
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Plasma cells (%)
Pre-dose value
N 0 0 0 0 1 1
Mean (SD) 0.0 0.0
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Post-dose value
N 1 0 2 2 0 5
Mean (SD) 0.0 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 30: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/30.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
12
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Promyelocytes (%)
Pre-dose value
N 0 0 0 0 1 1
Mean (SD) 0.0 0.0
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Post-dose value
N 1 0 2 2 0 5
Mean (SD) 0.0 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 31: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/31.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Bands (%)
Post-dose value
N 1 1 1 1 4
Mean (SD) 0.0 0.0 0.0 0.0 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 32: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/32.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Basophils (%)
Pre-dose value
N 2 2 3 2 9
Mean (SD) 0.3 (0.1) 0.9 (0.2) 0.3 (0.5) 0.2 (0.2) 0.4 (0.4)
Median (Min, Max) 0.3 (0.2, 0.3) 0.9 (0.7, 1.0) 0.0 (0.0, 0.9) 0.2 (0.0, 0.3) 0.3 (0.0, 1.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 0.0 (0.0) 0.5 (0.7) 0.3 (0.5) 0.0 0.2 (0.4)
Median (Min, Max) 0.0 (0.0, 0.0) 0.5 (0.0, 1.0) 0.0 (0.0, 1.0) 0.0 (0.0, 0.0) 0.0 (0.0, 1.0)
Change from Baseline
N 2 2 3 1 8
Mean (SD) -0.3 (0.1) -0.4 (0.5) 0.0 (0.1) 0.0 -0.1 (0.3)
Median (Min, Max) -0.3 (-0.3, -0.2) -0.4 (-0.7, 0.0) 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.0 (-0.7, 0.1)
95% CI for Median 1 (-0.3, 0.1)
Percentage Change
N 2 2 1 0 5
Mean (SD) -100.0 (0.0) -50.0 (70.7) 11.1 -57.8 (57.9)
Median (Min, Max) -100.0 (-100.0, -100.0) -50.0 (-100.0, 0.0) 11.1 (11.1, 11.1) -100.0 (-100.0, 11.1)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 33: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/33.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
3
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Blasts (%)
Post-dose value
N 1 1 1 1 4
Mean (SD) 0.0 0.0 0.0 0.0 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 34: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/34.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
4
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Eosinophils (%)
Pre-dose value
N 2 2 3 2 9
Mean (SD) 2.8 (0.4) 3.2 (1.1) 2.0 (1.0) 2.0 (1.4) 2.4 (1.0)
Median (Min, Max) 2.8 (2.5, 3.1) 3.2 (2.4, 4.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.5 (1.0, 4.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 1.0 (0.0) 5.5 (4.9) 2.0 (0.8) 1.0 2.4 (2.6)
Median (Min, Max) 1.0 (1.0, 1.0) 5.5 (2.0, 9.0) 2.0 (1.0, 3.0) 1.0 (1.0, 1.0) 2.0 (1.0, 9.0)
Change from Baseline
N 2 2 3 1 8
Mean (SD) -1.8 (0.4) 2.3 (3.8) -0.3 (0.6) 0.0 0.0 (2.2)
Median (Min, Max) -1.8 (-2.1, -1.5) 2.3 (-0.4, 5.0) 0.0 (-1.0, 0.0) 0.0 (0.0, 0.0) -0.2 (-2.1, 5.0)
95% CI for Median 1 (-1.5, 5.0)
Percentage Change
N 2 2 3 1 8
Mean (SD) -63.9 (5.5) 54.2 (100.2) -11.1 (19.2) 0.0 -6.6 (59.6)
Median (Min, Max) -63.9 (-67.7, -60.0) 54.2 (-16.7, 125.0) 0.0 (-33.3, 0.0) 0.0 (0.0, 0.0) -8.3 (-67.7, 125.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 35: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/35.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
5
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Lymphocytes (%)
Pre-dose value
N 2 2 4 2 10
Mean (SD) 27.0 (6.2) 40.7 (17.9) 31.3 (6.5) 33.4 (6.2) 32.7 (9.0)
Median (Min, Max) 27.0 (22.6, 31.3) 40.7 (28.0, 53.3) 30.0 (25.0, 40.0) 33.4 (29.0, 37.8) 30.2 (22.6, 53.3)
Post-dose value
N 2 2 4 1 9
Mean (SD) 29.5 (12.0) 37.5 (14.8) 35.0 (6.2) 52.0 36.2 (10.2)
Median (Min, Max) 29.5 (21.0, 38.0) 37.5 (27.0, 48.0) 35.5 (27.0, 42.0) 52.0 (52.0, 52.0) 36.0 (21.0, 52.0)
Change from Baseline
N 2 2 3 1 8
Mean (SD) 2.6 (5.9) -3.2 (3.0) 2.7 (13.6) 23.0 3.7 (11.2)
Median (Min, Max) 2.6 (-1.6, 6.7) -3.2 (-5.3, -1.0) 10.0 (-13.0, 11.0) 23.0 (23.0, 23.0) 2.9 (-13.0, 23.0)
95% CI for Median 1 (-5.3, 23.0)
Percentage Change
N 2 2 3 1 8
Mean (SD) 7.2 (20.1) -6.8 (4.5) 14.3 (41.0) 79.3 15.4 (35.8)
Median (Min, Max) 7.2 (-7.1, 21.4) -6.8 (-9.9, -3.6) 31.3 (-32.5, 44.0) 79.3 (79.3, 79.3) 8.9 (-32.5, 79.3)
Participant with at least one newly emergent abnormal finding
0 1 (50.0%) 0 1 (50.0%) 2 (18.2%)
![Page 36: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/36.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
6
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Metamyelocytes (%)
Post-dose value
N 1 1 1 1 4
Mean (SD) 0.0 0.0 0.0 0.0 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 37: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/37.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
7
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Monocytes (%)
Pre-dose value
N 2 2 4 2 10
Mean (SD) 5.7 (1.8) 6.7 (0.5) 7.9 (5.4) 4.9 (2.7) 6.6 (3.5)
Median (Min, Max) 5.7 (4.4, 7.0) 6.7 (6.3, 7.0) 7.2 (2.0, 15.0) 4.9 (3.0, 6.8) 6.6 (2.0, 15.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 7.5 (2.1) 7.0 (8.5) 5.5 (3.1) 4.0 6.1 (3.8)
Median (Min, Max) 7.5 (6.0, 9.0) 7.0 (1.0, 13.0) 5.5 (2.0, 9.0) 4.0 (4.0, 4.0) 6.0 (1.0, 13.0)
Change from Baseline
N 2 2 3 1 8
Mean (SD) 1.8 (0.3) 0.4 (9.0) -1.1 (1.2) 1.0 0.2 (3.7)
Median (Min, Max) 1.8 (1.6, 2.0) 0.4 (-6.0, 6.7) -1.0 (-2.4, 0.0) 1.0 (1.0, 1.0) 0.5 (-6.0, 6.7)
95% CI for Median 1 (-2.4, 6.7)
Percentage Change
N 2 2 3 1 8
Mean (SD) 32.5 (5.5) 10.3 (135.8) -16.7 (19.1) 33.3 8.6 (57.2)
Median (Min, Max) 32.5 (28.6, 36.4) 10.3 (-85.7, 106.3) -12.5 (-37.5, 0.0) 33.3 (33.3, 33.3) 14.3 (-85.7, 106.3)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 38: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/38.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
8
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Myelocytes (%)
Post-dose value
N 1 1 1 1 4
Mean (SD) 0.0 0.0 0.0 0.0 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 39: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/39.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
9
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Neutrophils (%)
Pre-dose value
N 2 1 2 2 7
Mean (SD) 64.1 (3.7) 61.0 60.5 (16.3) 59.5 (10.6) 61.3 (8.3)
Median (Min, Max) 64.1 (61.5, 66.7) 61.0 (61.0, 61.0) 60.5 (49.0, 72.0) 59.5 (52.0, 67.0) 61.5 (49.0, 72.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 61.5 (10.6) 50.0 (17.0) 57.3 (6.2) 44.0 55.1 (9.9)
Median (Min, Max) 61.5 (54.0, 69.0) 50.0 (38.0, 62.0) 56.5 (52.0, 64.0) 44.0 (44.0, 44.0) 54.0 (38.0, 69.0)
Change from Baseline
N 2 1 2 1 6
Mean (SD) -2.6 (6.9) 1.0 2.0 (18.4) -23.0 -3.9 (13.0)
Median (Min, Max) -2.6 (-7.5, 2.3) 1.0 (1.0, 1.0) 2.0 (-11.0, 15.0) -23.0 (-23.0, -23.0) -3.3 (-23.0, 15.0)
95% CI for Median 1 (-23.0, 15.0)
Percentage Change
N 2 1 2 1 6
Mean (SD) -4.4 (11.1) 1.6 7.7 (32.4) -34.3 -4.4 (21.9)
Median (Min, Max) -4.4 (-12.2, 3.4) 1.6 (1.6, 1.6) 7.7 (-15.3, 30.6) -34.3 (-34.3, -34.3) -5.3 (-34.3, 30.6)
Participant with at least one newly emergent abnormal finding
1 (50.0%) 0 1 (20.0%) 0 2 (18.2%)
![Page 40: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/40.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
10
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Nucleated RBC (%)
Post-dose value
N 1 1 1 1 4
Mean (SD) 0.0 0.0 0.0 0.0 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 41: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/41.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
11
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Plasma cells (%)
Post-dose value
N 1 1 1 1 4
Mean (SD) 0.0 0.0 0.0 0.0 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 42: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/42.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.2.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Differential
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
12
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Promyelocytes (%)
Post-dose value
N 1 1 1 1 4
Mean (SD) 0.0 0.0 0.0 0.0 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 43: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/43.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Albumin (g/dL)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 4.3 (0.4) 4.4 4.4 (0.2) 4.4 (0.1) 4.5 (0.1) 4.4 (0.2)
Median (Min, Max) 4.5 (3.9, 4.6) 4.4 (4.4, 4.4) 4.4 (4.2, 4.5) 4.4 (4.3, 4.5) 4.5 (4.4, 4.6) 4.4 (3.9, 4.6)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 4.2 (0.2) 4.2 4.3 (0.3) 4.3 (0.2) 4.3 (0.1) 4.3 (0.2)
Median (Min, Max) 4.1 (4.1, 4.5) 4.2 (4.2, 4.2) 4.5 (4.0, 4.5) 4.2 (4.0, 4.6) 4.3 (4.2, 4.4) 4.2 (4.0, 4.6)
Change from Baseline
N 3 1 3 5 2 14
Mean (SD) -0.1 (0.3) -0.2 -0.0 (0.2) -0.1 (0.3) -0.3 (0.1) -0.1 (0.2)
Median (Min, Max) -0.1 (-0.4, 0.2) -0.2 (-0.2, -0.2) 0.0 (-0.2, 0.1) -0.2 (-0.3, 0.3) -0.3 (-0.3, -0.2) -0.2 (-0.4, 0.3)
95% CI for Median 1 (-0.3, 0.1)
Percentage Change
N 3 1 3 5 2 14
Mean (SD) -2.0 (7.0) -4.6 -0.8 (3.6) -3.1 (5.8) -5.5 (1.6) -2.8 (4.7)
Median (Min, Max) -2.2 (-8.9, 5.1) -4.6 (-4.5, -4.5) 0.0 (-4.8, 2.3) -4.6 (-7.0, 7.0) -5.5 (-6.7, -4.3) -4.5 (-8.9, 7.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 44: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/44.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Alkaline phosphatase (U/L)
Pre-dose value
N 3 1 1 4 3 12
Mean (SD) 234.0 (138.0) 146.0 228.0 129.5 (54.8) 131.7 (119.4) 165.8 (96.6)
Median (Min, Max) 164.0 (145.0, 393.0) 146.0 (146.0, 146.0) 228.0 (228.0, 228.0) 138.0 (57.0, 185.0) 162.0 (0.0, 233.0) 158.0 (0.0, 393.0)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 210.7 (106.0) 158.0 165.3 (73.7) 130.4 (47.7) 174.5 (68.6) 163.4 (67.7)
Median (Min, Max) 164.0 (136.0, 332.0) 158.0 (158.0, 158.0) 154.0 (98.0, 244.0) 137.0 (60.0, 181.0) 174.5 (126.0, 223.0) 156.0 (60.0, 332.0)
Change from Baseline
N 3 1 1 4 2 11
Mean (SD) -23.3 (32.9) 12.0 16.0 -11.8 (10.5) 58.0 (96.2) 2.5 (45.8)
Median (Min, Max) -9.0 (-61.0, 0.0) 12.0 (12.0, 12.0) 16.0 (16.0, 16.0) -14.5 (-21.0, 3.0) 58.0 (-10.0, 126.0) -9.0 (-61.0, 126.0)
95% CI for Median 1 (-17.0, 16.0)
Percentage Change
N 3 1 1 4 1 10
Mean (SD) -7.2 (7.8) 8.2 7.0 -6.7 (8.0) -4.3 -3.8 (8.5)
Median (Min, Max) -6.2 (-15.5, 0.0) 8.2 (8.2, 8.2) 7.0 (7.0, 7.0) -10.4 (-11.4, 5.3) -4.3 (-4.3, -4.3) -5.3 (-15.5, 8.2)
Participant with at least one newly emergent abnormal finding
0 0 0 1 (20.0%) 0 1 (6.7%)
![Page 45: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/45.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
3
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
ALT (U/L)
Pre-dose value
N 3 1 1 5 3 13
Mean (SD) 49.3 (42.1) 18.0 10.0 19.2 (7.1) 10.0 (10.0) 23.2 (23.8)
Median (Min, Max) 52.0 (6.0, 90.0) 18.0 (18.0, 18.0) 10.0 (10.0, 10.0) 21.0 (7.0, 25.0) 10.0 (0.0, 20.0) 20.0 (0.0, 90.0)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 34.0 (23.5) 12.0 11.3 (2.9) 16.2 (9.6) 9.0 (2.8) 17.6 (14.2)
Median (Min, Max) 45.0 (7.0, 50.0) 12.0 (12.0, 12.0) 13.0 (8.0, 13.0) 12.0 (7.0, 28.0) 9.0 (7.0, 11.0) 12.0 (7.0, 50.0)
Change from Baseline
N 3 1 1 5 2 12
Mean (SD) -15.3 (21.7) -6.0 -2.0 -3.0 (8.9) 4.0 (9.9) -5.1 (13.0)
Median (Min, Max) -7.0 (-40.0, 1.0) -6.0 (-6.0, -6.0) -2.0 (-2.0, -2.0) 0.0 (-16.0, 5.0) 4.0 (-3.0, 11.0) -2.5 (-40.0, 11.0)
95% CI for Median 1 (-8.0, 4.0)
Percentage Change
N 3 1 1 5 1 11
Mean (SD) -13.8 (30.6) -33.3 -20.0 -12.6 (37.9) -30.0 -17.1 (28.6)
Median (Min, Max) -13.5 (-44.4, 16.7) -33.3 (-33.3, -33.3) -20.0 (-20.0, -20.0) 0.0 (-64.0, 21.7) -30.0 (-30.0, -30.0) -20.0 (-64.0, 21.7)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 46: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/46.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
4
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
AST (U/L)
Pre-dose value
N 3 1 1 5 3 13
Mean (SD) 44.0 (42.3) 23.0 35.0 24.0 (8.6) 16.7 (14.7) 27.7 (21.6)
Median (Min, Max) 28.0 (12.0, 92.0) 23.0 (23.0, 23.0) 35.0 (35.0, 35.0) 25.0 (11.0, 33.0) 22.0 (0.0, 28.0) 25.0 (0.0, 92.0)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 30.3 (23.6) 17.0 19.0 (2.0) 20.6 (6.4) 19.5 (0.7) 21.9 (11.0)
Median (Min, Max) 28.0 (8.0, 55.0) 17.0 (17.0, 17.0) 19.0 (17.0, 21.0) 21.0 (12.0, 30.0) 19.5 (19.0, 20.0) 19.5 (8.0, 55.0)
Change from Baseline
N 3 1 1 5 2 12
Mean (SD) -13.7 (20.3) -6.0 -14.0 -3.4 (4.7) 8.5 (16.3) -5.1 (13.0)
Median (Min, Max) -4.0 (-37.0, 0.0) -6.0 (-6.0, -6.0) -14.0 (-14.0, -14.0) -3.0 (-11.0, 1.0) 8.5 (-3.0, 20.0) -3.5 (-37.0, 20.0)
95% CI for Median 1 (-11.0, 0.0)
Percentage Change
N 3 1 1 5 1 11
Mean (SD) -24.5 (21.5) -26.1 -40.0 -10.5 (17.4) -13.6 -18.7 (17.6)
Median (Min, Max) -33.3 (-40.2, 0.0) -26.1 (-26.1, -26.1) -40.0 (-40.0, -40.0) -9.1 (-36.7, 9.1) -13.6 (-13.6, -13.6) -16.0 (-40.2, 9.1)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 47: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/47.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
5
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Bicarbonate (mEq/L)
Pre-dose value
N 3 1 3 4 3 14
Mean (SD) 21.0 (1.0) 22.0 23.7 (1.2) 22.3 (3.9) 22.7 (0.6) 22.4 (2.2)
Median (Min, Max) 21.0 (20.0, 22.0) 22.0 (22.0, 22.0) 23.0 (23.0, 25.0) 21.5 (19.0, 27.0) 23.0 (22.0, 23.0) 22.5 (19.0, 27.0)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 20.0 (2.6) 22.0 21.3 (1.5) 20.4 (2.7) 20.7 (3.1) 20.7 (2.3)
Median (Min, Max) 21.0 (17.0, 22.0) 22.0 (22.0, 22.0) 21.0 (20.0, 23.0) 20.0 (17.0, 24.0) 20.0 (18.0, 24.0) 21.0 (17.0, 24.0)
Change from Baseline
N 3 1 3 4 3 14
Mean (SD) -1.0 (1.7) 0.0 -2.3 (2.5) -1.5 (4.4) -2.0 (3.6) -1.6 (2.9)
Median (Min, Max) 0.0 (-3.0, 0.0) 0.0 (0.0, 0.0) -2.0 (-5.0, 0.0) -1.0 (-7.0, 3.0) -3.0 (-5.0, 2.0) -1.0 (-7.0, 3.0)
95% CI for Median 1 (-3.0, 1.0)
Percentage Change
N 3 1 3 4 3 14
Mean (SD) -5.0 (8.7) 0.0 -9.6 (10.0) -4.8 (19.7) -8.6 (15.9) -6.3 (12.8)
Median (Min, Max) 0.0 (-15.0, 0.0) 0.0 (0.0, 0.0) -8.7 (-20.0, 0.0) -2.9 (-29.2, 15.8) -13.0 (-21.7, 9.1) -4.4 (-29.2, 15.8)
Participant with at least one newly emergent abnormal finding
0 0 0 1 (20.0%) 1 (33.3%) 2 (13.3%)
![Page 48: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/48.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
6
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Bilirubin, direct (mg/dL)
Pre-dose value
N 1 1 0 4 3 9
Mean (SD) 0.2 0.3 0.1 (0.1) 0.1 (0.1) 0.1 (0.1)
Median (Min, Max) 0.2 (0.2, 0.2) 0.3 (0.3, 0.3) 0.1 (0.0, 0.2) 0.2 (0.0, 0.2) 0.2 (0.0, 0.3)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 0.2 (0.1) 0.2 0.2 (0.0) 0.2 (0.0) 0.2 (0.0) 0.2 (0.0)
Median (Min, Max) 0.2 (0.1, 0.2) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.2 (0.1, 0.2)
Change from Baseline
N 1 1 0 4 2 8
Mean (SD) 0.0 -0.1 0.1 (0.1) 0.1 (0.1) 0.1 (0.1)
Median (Min, Max) 0.0 (0.0, 0.0) -0.1 (-0.1, -0.1) 0.1 (0.0, 0.2) 0.1 (0.0, 0.2) 0.0 (-0.1, 0.2)
95% CI for Median 1 (0.0, 0.2)
Percentage Change
N 1 1 0 2 1 5
Mean (SD) 0.0 -33.3 0.0 (0.0) 0.0 -6.7 (14.9)
Median (Min, Max) 0.0 (0.0, 0.0) -33.3 (-33.3, -33.3) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (-33.3, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 49: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/49.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
7
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Bilirubin, total (mg/dL)
Pre-dose value
N 3 1 1 5 3 13
Mean (SD) 0.4 (0.1) 0.4 0.7 0.3 (0.1) 0.1 (0.1) 0.3 (0.2)
Median (Min, Max) 0.4 (0.3, 0.4) 0.4 (0.4, 0.4) 0.7 (0.7, 0.7) 0.3 (0.2, 0.5) 0.2 (0.0, 0.2) 0.3 (0.0, 0.7)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 0.2 (0.2) 0.2 0.2 (0.2) 0.1 (0.1) 0.1 (0.0) 0.2 (0.1)
Median (Min, Max) 0.2 (0.1, 0.4) 0.2 (0.2, 0.2) 0.1 (0.1, 0.4) 0.1 (0.1, 0.2) 0.1 (0.1, 0.1) 0.1 (0.1, 0.4)
Change from Baseline
N 3 1 1 5 2 12
Mean (SD) -0.1 (0.2) -0.2 -0.3 -0.2 (0.2) 0.0 (0.1) -0.1 (0.1)
Median (Min, Max) -0.1 (-0.3, 0.0) -0.2 (-0.2, -0.2) -0.3 (-0.3, -0.3) -0.1 (-0.4, 0.0) 0.0 (-0.1, 0.1) -0.1 (-0.4, 0.1)
95% CI for Median 1 (-0.3, 0.0)
Percentage Change
N 3 1 1 5 1 11
Mean (SD) -36.1 (37.6) -50.0 -42.9 -46.0 (31.1) -50.0 -43.7 (26.4)
Median (Min, Max) -33.3 (-75.0, 0.0) -50.0 (-50.0, -50.0) -42.9 (-42.9, -42.9) -50.0 (-80.0, 0.0) -50.0 (-50.0, -50.0) -50.0 (-80.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 50: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/50.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
8
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Blood urea nitrogen (BUN) (mg/dL)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 28.3 (3.1) 16.0 14.7 (2.1) 14.4 (4.7) 13.7 (4.5) 17.2 (6.7)
Median (Min, Max) 29.0 (25.0, 31.0) 16.0 (16.0, 16.0) 14.0 (13.0, 17.0) 14.0 (9.0, 22.0) 14.0 (9.0, 18.0) 14.0 (9.0, 31.0)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 33.3 (2.9) 17.0 19.3 (4.0) 11.8 (1.3) 15.7 (4.0) 18.7 (8.5)
Median (Min, Max) 35.0 (30.0, 35.0) 17.0 (17.0, 17.0) 20.0 (15.0, 23.0) 12.0 (10.0, 13.0) 18.0 (11.0, 18.0) 17.0 (10.0, 35.0)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) 5.0 (1.0) 1.0 4.7 (4.7) -2.6 (4.4) 2.0 (2.0) 1.5 (4.5)
Median (Min, Max) 5.0 (4.0, 6.0) 1.0 (1.0, 1.0) 3.0 (1.0, 10.0) -2.0 (-9.0, 3.0) 2.0 (0.0, 4.0) 2.0 (-9.0, 10.0)
95% CI for Median 1 (-1.0, 4.0)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) 17.9 (4.3) 6.3 33.9 (37.6) -11.7 (28.3) 16.9 (15.0) 10.2 (28.0)
Median (Min, Max) 20.0 (12.9, 20.7) 6.3 (6.3, 6.3) 17.7 (7.1, 76.9) -15.4 (-40.9, 33.3) 22.2 (0.0, 28.6) 12.9 (-40.9, 76.9)
Participant with at least one newly emergent abnormal finding
0 0 2 (66.7%) 0 0 2 (13.3%)
![Page 51: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/51.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
9
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Calcium (mg/dL)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 10.0 (0.5) 9.8 10.2 (0.2) 9.5 (0.4) 9.7 (0.3) 9.8 (0.4)
Median (Min, Max) 10.1 (9.5, 10.4) 9.8 (9.8, 9.8) 10.2 (10.0, 10.3) 9.4 (9.1, 10.0) 9.8 (9.4, 9.9) 9.8 (9.1, 10.4)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 9.9 (0.1) 10.4 9.9 (0.2) 9.5 (0.5) 9.8 (0.2) 9.8 (0.4)
Median (Min, Max) 9.9 (9.8, 10.0) 10.4 (10.4, 10.4) 10.0 (9.7, 10.1) 9.4 (9.0, 10.2) 9.9 (9.6, 10.0) 9.9 (9.0, 10.4)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) -0.1 (0.5) 0.6 -0.2 (0.3) 0.0 (0.3) 0.1 (0.1) 0.0 (0.3)
Median (Min, Max) -0.3 (-0.5, 0.5) 0.6 (0.6, 0.6) -0.3 (-0.5, 0.1) 0.0 (-0.3, 0.3) 0.2 (0.0, 0.2) 0.0 (-0.5, 0.6)
95% CI for Median 1 (-0.3, 0.2)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) -0.8 (5.4) 6.1 -2.3 (3.0) -0.0 (2.7) 1.4 (1.2) 0.1 (3.5)
Median (Min, Max) -3.0 (-4.8, 5.3) 6.1 (6.1, 6.1) -2.9 (-4.9, 1.0) 0.0 (-3.2, 3.3) 2.0 (0.0, 2.1) 0.0 (-4.9, 6.1)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 52: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/52.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
10
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Chloride (mEq/L)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 105.3 (2.1) 103.0 102.0 (3.5) 103.2 (2.3) 101.7 (1.5) 103.1 (2.4)
Median (Min, Max) 106.0 (103.0, 107.0) 103.0 (103.0, 103.0) 104.0 (98.0, 104.0) 104.0 (100.0, 106.0) 102.0 (100.0, 103.0) 103.0 (98.0, 107.0)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 105.0 (2.6) 102.0 102.7 (1.5) 103.2 (3.1) 103.7 (2.1) 103.5 (2.4)
Median (Min, Max) 104.0 (103.0, 108.0) 102.0 (102.0, 102.0) 103.0 (101.0, 104.0) 103.0 (100.0, 108.0) 103.0 (102.0, 106.0) 103.0 (100.0, 108.0)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) -0.3 (1.5) -1.0 0.7 (4.0) 0.0 (1.2) 2.0 (3.5) 0.4 (2.4)
Median (Min, Max) 0.0 (-2.0, 1.0) -1.0 (-1.0, -1.0) 0.0 (-3.0, 5.0) 0.0 (-1.0, 2.0) 0.0 (0.0, 6.0) 0.0 (-3.0, 6.0)
95% CI for Median 1 (-1.0, 1.0)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) -0.3 (1.4) -1.0 0.7 (4.0) -0.0 (1.2) 2.0 (3.5) 0.4 (2.4)
Median (Min, Max) 0.0 (-1.9, 0.9) -1.0 (-1.0, -1.0) 0.0 (-2.9, 5.1) 0.0 (-1.0, 1.9) 0.0 (0.0, 6.0) 0.0 (-2.9, 6.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 53: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/53.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
11
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Cholesterol (mg/dL)
Pre-dose value
N 1 1 1 4 3 10
Mean (SD) 72.0 163.0 131.0 177.8 (31.2) 141.3 (127.6) 150.1 (71.0)
Median (Min, Max) 72.0 (72.0, 72.0) 163.0 (163.0, 163.0) 131.0 (131.0, 131.0) 165.5 (156.0, 224.0) 176.0 (0.0, 248.0) 164.0 (0.0, 248.0)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 162.3 (69.5) 155.0 149.0 (21.0) 168.8 (40.2) 178.5 (4.9) 163.6 (37.5)
Median (Min, Max) 162.0 (93.0, 232.0) 155.0 (155.0, 155.0) 158.0 (125.0, 164.0) 163.0 (122.0, 229.0) 178.5 (175.0, 182.0) 162.5 (93.0, 232.0)
Change from Baseline
N 1 1 1 4 2 9
Mean (SD) 21.0 -8.0 -6.0 -12.3 (17.1) 54.5 (170.4) 7.4 (67.5)
Median (Min, Max) 21.0 (21.0, 21.0) -8.0 (-8.0, -8.0) -6.0 (-6.0, -6.0) -10.0 (-34.0, 5.0) 54.5 (-66.0, 175.0) -6.0 (-66.0, 175.0)
95% CI for Median 1 (-34.0, 21.0)
Percentage Change
N 1 1 1 4 1 8
Mean (SD) 29.2 -4.9 -4.6 -7.9 (10.6) -26.6 -4.8 (16.9)
Median (Min, Max) 29.2 (29.2, 29.2) -4.9 (-4.9, -4.9) -4.6 (-4.6, -4.6) -6.1 (-21.8, 2.2) -26.6 (-26.6, -26.6) -4.7 (-26.6, 29.2)
Participant with at least one newly emergent abnormal finding
1 (33.3%) 0 0 0 1 (33.3%) 2 (13.3%)
![Page 54: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/54.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
12
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Creatinine (mg/dL)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 1.8 (0.6) 1.3 0.7 (0.1) 0.8 (0.2) 0.6 (0.2) 1.0 (0.5)
Median (Min, Max) 2.0 (1.1, 2.3) 1.3 (1.3, 1.3) 0.7 (0.6, 0.8) 0.8 (0.6, 1.0) 0.6 (0.4, 0.8) 0.8 (0.4, 2.3)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 1.6 (0.4) 1.2 0.7 (0.1) 0.8 (0.2) 0.7 (0.2) 1.0 (0.4)
Median (Min, Max) 1.8 (1.1, 1.8) 1.2 (1.2, 1.2) 0.7 (0.6, 0.8) 0.8 (0.7, 1.1) 0.8 (0.5, 0.8) 0.8 (0.5, 1.8)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) -0.2 (0.3) -0.1 0.0 (0.0) 0.0 (0.1) 0.1 (0.1) -0.0 (0.2)
Median (Min, Max) -0.2 (-0.5, 0.0) -0.1 (-0.1, -0.1) 0.0 (0.0, 0.0) 0.1 (-0.1, 0.1) 0.1 (-0.0, 0.2) 0.0 (-0.5, 0.2)
95% CI for Median 1 (-0.1, 0.1)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) -8.6 (12.3) -7.7 4.4 (1.3) 3.8 (8.5) 13.2 (15.7) 2.6 (11.7)
Median (Min, Max) -8.5 (-20.9, 3.8) -7.7 (-7.7, -7.7) 5.1 (2.9, 5.3) 7.8 (-7.2, 13.2) 16.3 (-3.8, 27.1) 3.8 (-20.9, 27.1)
Participant with at least one newly emergent abnormal finding
0 0 0 0 2 (66.7%) 2 (13.3%)
![Page 55: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/55.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
13
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Glucose (mg/dL)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 79.3 (8.5) 109.0 92.0 (9.6) 96.6 (12.2) 101.3 (11.0) 94.0 (12.7)
Median (Min, Max) 76.0 (73.0, 89.0) 109.0 (109.0, 109.0) 96.0 (81.0, 99.0) 94.0 (84.0, 117.0) 105.0 (89.0, 110.0) 94.0 (73.0, 117.0)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 85.0 (10.4) 113.0 84.0 (8.7) 92.2 (18.7) 85.0 (3.6) 89.1 (13.6)
Median (Min, Max) 90.0 (73.0, 92.0) 113.0 (113.0, 113.0) 88.0 (74.0, 90.0) 91.0 (74.0, 122.0) 84.0 (82.0, 89.0) 89.0 (73.0, 122.0)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) 5.7 (7.4) 4.0 -8.0 (2.6) -4.4 (23.6) -16.3 (11.5) -4.9 (15.7)
Median (Min, Max) 3.0 (0.0, 14.0) 4.0 (4.0, 4.0) -7.0 (-11.0, -6.0) -2.0 (-38.0, 28.0) -16.0 (-28.0, -5.0) -5.0 (-38.0, 28.0)
95% CI for Median 1 (-11.0, 3.0)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) 7.3 (9.8) 3.7 -8.7 (2.4) -3.4 (22.5) -15.4 (9.9) -4.2 (15.4)
Median (Min, Max) 3.4 (0.0, 18.4) 3.7 (3.7, 3.7) -8.6 (-11.1, -6.3) -2.2 (-32.5, 29.8) -15.2 (-25.5, -5.6) -5.6 (-32.5, 29.8)
Participant with at least one newly emergent abnormal finding
0 1 (100.0%) 0 0 0 1 (6.7%)
![Page 56: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/56.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
14
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Phosphorus (mg/dL)
Pre-dose value
N 2 1 2 4 3 12
Mean (SD) 3.7 (0.1) 4.2 4.7 (0.4) 4.3 (0.7) 4.3 (0.3) 4.3 (0.5)
Median (Min, Max) 3.7 (3.6, 3.7) 4.2 (4.2, 4.2) 4.7 (4.4, 5.0) 4.4 (3.7, 4.9) 4.5 (4.0, 4.5) 4.3 (3.6, 5.0)
Post-dose value
N 0 0 0 0 1 1
Mean (SD) 5.0 5.0
Median (Min, Max) 5.0 (5.0, 5.0) 5.0 (5.0, 5.0)
Change from Baseline
N 0 0 0 0 1 1
Mean (SD) 1.0 1.0
Median (Min, Max) 1.0 (1.0, 1.0) 1.0 (1.0, 1.0)
95% CI for Median 1 (., .)
Percentage Change
N 0 0 0 0 1 1
Mean (SD) 25.0 25.0
Median (Min, Max) 25.0 (25.0, 25.0) 25.0 (25.0, 25.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0 0
![Page 57: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/57.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
15
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Potassium (mEq/L)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 4.8 (0.4) 4.1 4.1 (0.4) 4.3 (0.3) 4.2 (0.8) 4.3 (0.5)
Median (Min, Max) 4.9 (4.3, 5.1) 4.1 (4.1, 4.1) 4.2 (3.6, 4.4) 4.2 (4.0, 4.8) 4.5 (3.3, 4.9) 4.3 (3.3, 5.1)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 5.0 (0.5) 4.3 4.3 (0.5) 3.9 (0.5) 4.5 (0.5) 4.4 (0.6)
Median (Min, Max) 4.8 (4.6, 5.6) 4.3 (4.3, 4.3) 4.3 (3.9, 4.8) 3.6 (3.5, 4.6) 4.6 (4.0, 5.0) 4.3 (3.5, 5.6)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) 0.2 (0.3) 0.2 0.3 (0.2) -0.4 (0.6) 0.3 (0.5) 0.1 (0.5)
Median (Min, Max) 0.3 (-0.1, 0.5) 0.2 (0.2, 0.2) 0.3 (0.1, 0.4) -0.4 (-1.3, 0.4) 0.5 (-0.3, 0.7) 0.2 (-1.3, 0.7)
95% CI for Median 1 (-0.3, 0.4)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) 4.9 (6.2) 4.9 6.6 (3.7) -8.0 (13.3) 8.7 (13.8) 1.7 (11.7)
Median (Min, Max) 7.0 (-2.0, 9.8) 4.9 (4.9, 4.9) 8.3 (2.4, 9.1) -10.0 (-27.1, 9.5) 11.1 (-6.1, 21.2) 4.9 (-27.1, 21.2)
Participant with at least one newly emergent abnormal finding
1 (33.3%) 0 0 0 0 1 (6.7%)
![Page 58: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/58.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
16
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Protein, total (g/d)
Pre-dose value
N 3 1 2 4 3 13
Mean (SD) 7.3 (0.6) 7.2 8.3 (0.1) 7.2 (0.5) 4.4 (3.8) 6.8 (2.1)
Median (Min, Max) 7.2 (6.8, 8.0) 7.2 (7.2, 7.2) 8.3 (8.2, 8.3) 7.1 (6.8, 7.9) 6.4 (0.0, 6.8) 7.2 (0.0, 8.3)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 7.0 (0.9) 6.8 7.3 (0.3) 6.7 (0.7) 6.0 (0.2) 6.8 (0.7)
Median (Min, Max) 6.5 (6.4, 8.0) 6.8 (6.8, 6.8) 7.4 (7.0, 7.5) 6.5 (6.0, 7.5) 6.0 (5.8, 6.1) 6.7 (5.8, 8.0)
Change from Baseline
N 3 1 2 4 2 12
Mean (SD) -0.4 (0.4) -0.4 -0.8 (0.1) -0.7 (0.4) 2.6 (4.6) -0.1 (1.9)
Median (Min, Max) -0.4 (-0.7, 0.0) -0.4 (-0.4, -0.4) -0.8 (-0.9, -0.7) -0.6 (-1.1, -0.3) 2.6 (-0.7, 5.8) -0.6 (-1.1, 5.8)
95% CI for Median 1 (-0.8, -0.3)
Percentage Change
N 3 1 2 4 1 11
Mean (SD) -5.2 (4.9) -5.6 -9.7 (1.6) -9.0 (5.1) -10.3 -7.9 (4.2)
Median (Min, Max) -5.9 (-9.7, 0.0) -5.6 (-5.6, -5.6) -9.7 (-10.8, -8.5) -8.4 (-14.9, -4.4) -10.3 (-10.3, -10.3) -8.5 (-14.9, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 1 (33.3%) 1 (6.7%)
![Page 59: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/59.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
17
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Sodium (mEq/L)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 138.7 (1.5) 139.0 139.0 (2.6) 138.4 (2.9) 141.0 (1.0) 139.1 (2.2)
Median (Min, Max) 139.0 (137.0, 140.0) 139.0 (139.0, 139.0) 140.0 (136.0, 141.0) 138.0 (134.0, 141.0) 141.0 (140.0, 142.0) 140.0 (134.0, 142.0)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 138.3 (1.5) 139.0 137.7 (0.6) 137.8 (3.2) 138.7 (5.1) 138.1 (2.7)
Median (Min, Max) 138.0 (137.0, 140.0) 139.0 (139.0, 139.0) 138.0 (137.0, 138.0) 137.0 (134.0, 142.0) 140.0 (133.0, 143.0) 138.0 (133.0, 143.0)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) -0.3 (1.5) 0.0 -1.3 (3.1) -0.6 (2.4) -2.3 (5.9) -1.0 (3.0)
Median (Min, Max) 0.0 (-2.0, 1.0) 0.0 (0.0, 0.0) -2.0 (-4.0, 2.0) 0.0 (-4.0, 2.0) 0.0 (-9.0, 2.0) 0.0 (-9.0, 2.0)
95% CI for Median 1 (-2.0, 1.0)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) -0.2 (1.1) 0.0 -0.9 (2.2) -0.4 (1.7) -1.6 (4.1) -0.7 (2.1)
Median (Min, Max) 0.0 (-1.4, 0.7) 0.0 (0.0, 0.0) -1.4 (-2.8, 1.5) 0.0 (-2.8, 1.4) 0.0 (-6.3, 1.4) 0.0 (-6.3, 1.5)
Participant with at least one newly emergent abnormal finding
0 0 0 0 1 (33.3%) 1 (6.7%)
![Page 60: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/60.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
18
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Calculated eGFR (mL/min per 1.73m²)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 37.5 (12.1) 52.6 90.3 (13.7) 78.1 (12.7) 92.7 (32.0) 73.6 (26.4)
Median (Min, Max) 31.3 (29.6, 51.5) 52.6 (52.6, 52.6) 87.7 (78.1, 105.1) 74.8 (63.6, 98.2) 99.7 (57.9, 120.6) 74.8 (29.6, 120.6)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 40.4 (8.1) 57.0 86.4 (12.2) 78.2 (17.4) 92.9 (42.0) 73.8 (27.3)
Median (Min, Max) 37.5 (34.3, 49.6) 57.0 (57.0, 57.0) 83.5 (75.9, 99.8) 76.5 (59.0, 103.3) 78.4 (60.1, 140.2) 75.9 (34.3, 140.2)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) 3.0 (4.8) 4.4 -3.9 (1.6) 0.1 (6.5) 0.2 (20.5) 0.2 (9.1)
Median (Min, Max) 2.9 (-1.9, 7.8) 4.4 (4.4, 4.4) -4.3 (-5.3, -2.2) 2.3 (-8.7, 6.2) 2.3 (-21.3, 19.6) 2.3 (-21.3, 19.6)
95% CI for Median 1 (-4.6, 5.2)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) 10.7 (15.1) 8.3 -4.2 (1.2) -0.6 (8.4) -0.4 (19.1) 1.6 (11.7)
Median (Min, Max) 9.3 (-3.6, 26.4) 8.3 (8.3, 8.3) -4.9 (-5.0, -2.8) 3.0 (-11.7, 7.8) 3.9 (-21.3, 16.2) 3.0 (-21.3, 26.4)
Participant with at least one newly emergent abnormal finding
0 0 0 0 2 (66.7%) 2 (13.3%)
![Page 61: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/61.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Albumin (g/dL)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 4.5 (0.2) 4.2 (0.0) 4.5 (0.3) 4.4 (0.3) 4.4 (0.3)
Median (Min, Max) 4.5 (4.3, 4.6) 4.2 (4.2, 4.2) 4.5 (4.0, 4.9) 4.4 (4.2, 4.6) 4.5 (4.0, 4.9)
Post-dose value
N 2 2 4 1 9
Mean (SD) 4.4 (0.1) 3.8 (0.3) 4.5 (0.1) 4.4 4.3 (0.3)
Median (Min, Max) 4.4 (4.3, 4.4) 3.8 (3.6, 4.0) 4.6 (4.3, 4.6) 4.4 (4.4, 4.4) 4.4 (3.6, 4.6)
Change from Baseline
N 2 2 4 1 9
Mean (SD) -0.1 (0.1) -0.4 (0.3) 0.0 (0.4) -0.2 -0.1 (0.3)
Median (Min, Max) -0.1 (-0.2, 0.0) -0.4 (-0.6, -0.2) -0.2 (-0.3, 0.6) -0.2 (-0.2, -0.2) -0.2 (-0.6, 0.6)
95% CI for Median 1 (-0.3, 0.0)
Percentage Change
N 2 2 4 1 9
Mean (SD) -2.2 (3.1) -9.5 (6.7) 0.6 (9.8) -4.4 -2.8 (7.7)
Median (Min, Max) -2.2 (-4.3, 0.0) -9.5 (-14.3, -4.8) -3.3 (-6.1, 15.0) -4.4 (-4.3, -4.3) -4.4 (-14.3, 15.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 62: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/62.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Alkaline phosphatase (U/L)
Pre-dose value
N 2 1 5 2 10
Mean (SD) 181.0 (89.1) 142.0 136.8 (38.4) 221.0 (8.5) 163.0 (52.9)
Median (Min, Max) 181.0 (118.0, 244.0) 142.0 (142.0, 142.0) 123.0 (96.0, 193.0) 221.0 (215.0, 227.0) 149.5 (96.0, 244.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 172.0 (93.3) 240.5 (164.8) 135.3 (32.2) 198.0 173.8 (82.5)
Median (Min, Max) 172.0 (106.0, 238.0) 240.5 (124.0, 357.0) 130.5 (107.0, 173.0) 198.0 (198.0, 198.0) 151.0 (106.0, 357.0)
Change from Baseline
N 2 1 4 1 8
Mean (SD) -9.0 (4.2) -18.0 -7.0 (13.3) -29.0 -11.6 (11.9)
Median (Min, Max) -9.0 (-12.0, -6.0) -18.0 (-18.0, -18.0) -9.5 (-20.0, 11.0) -29.0 (-29.0, -29.0) -12.5 (-29.0, 11.0)
95% CI for Median 1 (-20.0, 11.0)
Percentage Change
N 2 1 4 1 8
Mean (SD) -6.3 (5.5) -12.7 -3.3 (10.3) -12.8 -6.4 (8.2)
Median (Min, Max) -6.3 (-10.2, -2.5) -12.7 (-12.7, -12.7) -7.1 (-10.6, 11.5) -12.8 (-12.8, -12.8) -10.3 (-12.8, 11.5)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 63: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/63.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
3
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
ALT (U/L)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 23.5 (13.4) 25.0 (26.9) 20.8 (8.9) 21.5 (12.0) 22.2 (11.8)
Median (Min, Max) 23.5 (14.0, 33.0) 25.0 (6.0, 44.0) 20.0 (10.0, 32.0) 21.5 (13.0, 30.0) 20.0 (6.0, 44.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 25.0 (17.0) 21.5 (20.5) 13.5 (3.8) 9.0 17.3 (11.4)
Median (Min, Max) 25.0 (13.0, 37.0) 21.5 (7.0, 36.0) 15.0 (8.0, 16.0) 9.0 (9.0, 9.0) 14.0 (7.0, 37.0)
Change from Baseline
N 2 2 4 1 9
Mean (SD) 1.5 (3.5) -3.5 (6.4) -4.5 (6.0) -4.0 -2.9 (5.2)
Median (Min, Max) 1.5 (-1.0, 4.0) -3.5 (-8.0, 1.0) -3.0 (-13.0, 1.0) -4.0 (-4.0, -4.0) -2.0 (-13.0, 4.0)
95% CI for Median 1 (-8.0, 1.0)
Percentage Change
N 2 2 4 1 9
Mean (SD) 2.5 (13.6) -0.8 (24.6) -20.4 (22.4) -30.8 -12.1 (21.2)
Median (Min, Max) 2.5 (-7.1, 12.1) -0.8 (-18.2, 16.7) -20.0 (-48.1, 6.7) -30.8 (-30.8, -30.8) -18.2 (-48.1, 16.7)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 64: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/64.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
4
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
AST (U/L)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 20.0 (7.1) 34.5 (23.3) 21.2 (7.9) 30.0 (4.2) 25.0 (11.0)
Median (Min, Max) 20.0 (15.0, 25.0) 34.5 (18.0, 51.0) 23.0 (13.0, 32.0) 30.0 (27.0, 33.0) 24.0 (13.0, 51.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 23.0 (7.1) 38.5 (6.4) 16.8 (4.5) 25.0 23.9 (9.9)
Median (Min, Max) 23.0 (18.0, 28.0) 38.5 (34.0, 43.0) 15.5 (13.0, 23.0) 25.0 (25.0, 25.0) 23.0 (13.0, 43.0)
Change from Baseline
N 2 2 4 1 9
Mean (SD) 3.0 (0.0) 4.0 (17.0) -1.8 (5.1) -2.0 0.6 (7.3)
Median (Min, Max) 3.0 (3.0, 3.0) 4.0 (-8.0, 16.0) -0.5 (-9.0, 3.0) -2.0 (-2.0, -2.0) 0.0 (-9.0, 16.0)
95% CI for Median 1 (-8.0, 3.0)
Percentage Change
N 2 2 4 1 9
Mean (SD) 16.0 (5.7) 36.6 (73.9) -5.5 (25.1) -7.4 8.4 (35.6)
Median (Min, Max) 16.0 (12.0, 20.0) 36.6 (-15.7, 88.9) -2.1 (-39.1, 21.4) -7.4 (-7.4, -7.4) 0.0 (-39.1, 88.9)
Participant with at least one newly emergent abnormal finding
0 1 (50.0%) 0 0 1 (9.1%)
![Page 65: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/65.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
5
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Bicarbonate (mEq/L)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 19.0 (0.0) 19.5 (3.5) 23.6 (1.1) 24.5 (3.5) 22.2 (2.9)
Median (Min, Max) 19.0 (19.0, 19.0) 19.5 (17.0, 22.0) 24.0 (22.0, 25.0) 24.5 (22.0, 27.0) 22.0 (17.0, 27.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 18.0 (5.7) 19.0 (1.4) 21.0 (3.2) 20.0 19.8 (3.1)
Median (Min, Max) 18.0 (14.0, 22.0) 19.0 (18.0, 20.0) 20.5 (18.0, 25.0) 20.0 (20.0, 20.0) 20.0 (14.0, 25.0)
Change from Baseline
N 2 2 4 1 9
Mean (SD) -1.0 (5.7) -0.5 (2.1) -2.5 (3.4) -2.0 -1.7 (3.1)
Median (Min, Max) -1.0 (-5.0, 3.0) -0.5 (-2.0, 1.0) -3.0 (-6.0, 2.0) -2.0 (-2.0, -2.0) -2.0 (-6.0, 3.0)
95% CI for Median 1 (-5.0, 2.0)
Percentage Change
N 2 2 4 1 9
Mean (SD) -5.3 (29.8) -1.6 (10.6) -10.5 (14.3) -9.1 -7.2 (14.7)
Median (Min, Max) -5.3 (-26.3, 15.8) -1.6 (-9.1, 5.9) -13.3 (-24.0, 8.7) -9.1 (-9.1, -9.1) -9.1 (-26.3, 15.8)
Participant with at least one newly emergent abnormal finding
1 (50.0%) 0 2 (40.0%) 0 3 (27.3%)
![Page 66: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/66.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
6
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Bilirubin, direct (mg/dL)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 0.2 (0.0) 0.1 (0.1) 0.1 (0.1) 0.2 (0.0) 0.2 (0.1)
Median (Min, Max) 0.2 (0.2, 0.2) 0.1 (0.0, 0.2) 0.2 (0.0, 0.2) 0.2 (0.2, 0.2) 0.2 (0.0, 0.2)
Post-dose value
N 2 2 4 1 9
Mean (SD) 0.2 (0.0) 0.2 (0.0) 0.2 (0.0) 0.2 0.2 (0.0)
Median (Min, Max) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2)
Change from Baseline
N 2 2 4 1 9
Mean (SD) 0.0 (0.0) 0.1 (0.1) 0.1 (0.1) 0.0 0.0 (0.1)
Median (Min, Max) 0.0 (0.0, 0.0) 0.1 (0.0, 0.2) 0.0 (0.0, 0.2) 0.0 (0.0, 0.0) 0.0 (0.0, 0.2)
95% CI for Median 1 (0.0, 0.2)
Percentage Change
N 2 1 3 1 7
Mean (SD) 0.0 (0.0) 0.0 0.0 (0.0) 0.0 0.0 (0.0)
Median (Min, Max) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 67: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/67.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
7
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Bilirubin, total (mg/dL)
Pre-dose value
N 2 1 5 2 10
Mean (SD) 0.2 (0.0) 0.1 0.2 (0.1) 0.1 (0.0) 0.2 (0.1)
Median (Min, Max) 0.2 (0.2, 0.2) 0.1 (0.1, 0.1) 0.2 (0.1, 0.3) 0.1 (0.1, 0.1) 0.2 (0.1, 0.3)
Post-dose value
N 2 2 4 1 9
Mean (SD) 0.3 (0.2) 0.2 (0.1) 0.2 (0.1) 0.1 0.2 (0.1)
Median (Min, Max) 0.3 (0.1, 0.4) 0.2 (0.1, 0.2) 0.2 (0.1, 0.2) 0.1 (0.1, 0.1) 0.1 (0.1, 0.4)
Change from Baseline
N 2 1 4 1 8
Mean (SD) 0.1 (0.2) 0.1 -0.1 (0.1) 0.0 -0.0 (0.1)
Median (Min, Max) 0.1 (-0.1, 0.2) 0.1 (0.1, 0.1) -0.1 (-0.2, 0.0) 0.0 (0.0, 0.0) 0.0 (-0.2, 0.2)
95% CI for Median 1 (-0.1, 0.2)
Percentage Change
N 2 1 4 1 8
Mean (SD) 25.0 (106.1) 100.0 -25.0 (31.9) 0.0 6.3 (63.0)
Median (Min, Max) 25.0 (-50.0, 100.0) 100.0 (100.0, 100.0) -16.7 (-66.7, 0.0) 0.0 (0.0, 0.0) 0.0 (-66.7, 100.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 68: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/68.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
8
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Blood urea nitrogen (BUN) (mg/dL)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 26.5 (6.4) 26.0 (7.1) 15.4 (3.0) 29.5 (4.9) 21.9 (7.4)
Median (Min, Max) 26.5 (22.0, 31.0) 26.0 (21.0, 31.0) 15.0 (12.0, 19.0) 29.5 (26.0, 33.0) 21.0 (12.0, 33.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 30.0 (11.3) 25.0 (12.7) 16.3 (3.4) 26.0 22.3 (8.8)
Median (Min, Max) 30.0 (22.0, 38.0) 25.0 (16.0, 34.0) 15.5 (13.0, 21.0) 26.0 (26.0, 26.0) 21.0 (13.0, 38.0)
Change from Baseline
N 2 2 4 1 9
Mean (SD) 3.5 (4.9) -1.0 (5.7) 0.8 (4.6) -7.0 0.1 (5.0)
Median (Min, Max) 3.5 (0.0, 7.0) -1.0 (-5.0, 3.0) 2.5 (-6.0, 4.0) -7.0 (-7.0, -7.0) 2.0 (-7.0, 7.0)
95% CI for Median 1 (-6.0, 4.0)
Percentage Change
N 2 2 4 1 9
Mean (SD) 11.3 (16.0) -7.1 (23.7) 8.5 (27.9) -21.2 2.3 (22.9)
Median (Min, Max) 11.3 (0.0, 22.6) -7.1 (-23.8, 9.7) 16.0 (-31.6, 33.3) -21.2 (-21.2, -21.2) 9.7 (-31.6, 33.3)
Participant with at least one newly emergent abnormal finding
2 (100.0%) 1 (50.0%) 1 (20.0%) 0 4 (36.4%)
![Page 69: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/69.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
9
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Calcium (mg/dL)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 9.7 (0.0) 9.6 (0.1) 9.9 (0.8) 10.0 (0.6) 9.8 (0.5)
Median (Min, Max) 9.7 (9.7, 9.7) 9.6 (9.5, 9.7) 9.8 (9.1, 11.0) 10.0 (9.5, 10.4) 9.7 (9.1, 11.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 9.5 (0.0) 9.5 (0.1) 9.8 (0.1) 9.9 9.7 (0.2)
Median (Min, Max) 9.5 (9.5, 9.5) 9.5 (9.4, 9.5) 9.8 (9.6, 9.9) 9.9 (9.9, 9.9) 9.6 (9.4, 9.9)
Change from Baseline
N 2 2 4 1 9
Mean (SD) -0.2 (0.0) -0.2 (0.1) -0.3 (0.7) -0.5 -0.3 (0.4)
Median (Min, Max) -0.2 (-0.2, -0.2) -0.2 (-0.2, -0.1) -0.4 (-1.1, 0.5) -0.5 (-0.5, -0.5) -0.2 (-1.1, 0.5)
95% CI for Median 1 (-0.5, -0.1)
Percentage Change
N 2 2 4 1 9
Mean (SD) -2.1 (0.0) -1.6 (0.7) -2.9 (6.4) -4.8 -2.6 (4.1)
Median (Min, Max) -2.1 (-2.1, -2.1) -1.6 (-2.1, -1.1) -3.5 (-10.0, 5.4) -4.8 (-4.8, -4.8) -2.1 (-10.0, 5.4)
Participant with at least one newly emergent abnormal finding
0 0 1 (20.0%) 0 1 (9.1%)
![Page 70: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/70.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
10
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Chloride (mEq/L)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 106.0 (1.4) 108.0 (2.8) 102.8 (2.4) 104.5 (4.9) 104.6 (3.2)
Median (Min, Max) 106.0 (105.0, 107.0) 108.0 (106.0, 110.0) 103.0 (100.0, 106.0) 104.5 (101.0, 108.0) 105.0 (100.0, 110.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 106.5 (0.7) 104.5 (0.7) 102.0 (2.9) 105.0 103.9 (2.7)
Median (Min, Max) 106.5 (106.0, 107.0) 104.5 (104.0, 105.0) 102.0 (99.0, 105.0) 105.0 (105.0, 105.0) 105.0 (99.0, 107.0)
Change from Baseline
N 2 2 4 1 9
Mean (SD) 0.5 (2.1) -3.5 (2.1) 0.0 (3.4) -3.0 -1.0 (2.9)
Median (Min, Max) 0.5 (-1.0, 2.0) -3.5 (-5.0, -2.0) 0.0 (-4.0, 4.0) -3.0 (-3.0, -3.0) -1.0 (-5.0, 4.0)
95% CI for Median 1 (-4.0, 2.0)
Percentage Change
N 2 2 4 1 9
Mean (SD) 0.5 (2.0) -3.2 (1.9) 0.0 (3.3) -2.8 -0.9 (2.8)
Median (Min, Max) 0.5 (-0.9, 1.9) -3.2 (-4.5, -1.9) -0.0 (-3.9, 4.0) -2.8 (-2.8, -2.8) -1.0 (-4.5, 4.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 71: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/71.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
11
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Cholesterol (mg/dL)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 153.5 (14.8) 166.0 (19.8) 190.4 (22.6) 140.0 (55.2) 170.1 (31.9)
Median (Min, Max) 153.5 (143.0, 164.0) 166.0 (152.0, 180.0) 190.0 (165.0, 213.0) 140.0 (101.0, 179.0) 171.0 (101.0, 213.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 151.0 (14.1) 146.0 (9.9) 169.0 (22.7) 137.0 156.3 (19.8)
Median (Min, Max) 151.0 (141.0, 161.0) 146.0 (139.0, 153.0) 168.0 (146.0, 194.0) 137.0 (137.0, 137.0) 153.0 (137.0, 194.0)
Change from Baseline
N 2 2 4 1 9
Mean (SD) -2.5 (0.7) -20.0 (29.7) -21.5 (28.7) -42.0 -19.2 (23.6)
Median (Min, Max) -2.5 (-3.0, -2.0) -20.0 (-41.0, 1.0) -19.0 (-59.0, 11.0) -42.0 (-42.0, -42.0) -19.0 (-59.0, 11.0)
95% CI for Median 1 (-42.0, 1.0)
Percentage Change
N 2 2 4 1 9
Mean (SD) -1.6 (0.3) -11.1 (16.6) -10.4 (14.0) -23.5 -10.1 (12.2)
Median (Min, Max) -1.6 (-1.8, -1.4) -11.1 (-22.8, 0.7) -10.2 (-27.7, 6.4) -23.5 (-23.5, -23.5) -8.9 (-27.7, 6.4)
Participant with at least one newly emergent abnormal finding
0 0 1 (20.0%) 0 1 (9.1%)
![Page 72: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/72.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
12
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Creatinine (mg/dL)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 1.5 (0.5) 1.5 (1.0) 0.8 (0.3) 0.9 (0.2) 1.1 (0.5)
Median (Min, Max) 1.5 (1.1, 1.8) 1.5 (0.8, 2.2) 0.7 (0.4, 1.2) 0.9 (0.8, 1.1) 1.0 (0.4, 2.2)
Post-dose value
N 2 2 4 1 9
Mean (SD) 1.5 (0.5) 1.5 (0.9) 0.9 (0.3) 0.6 1.2 (0.6)
Median (Min, Max) 1.5 (1.2, 1.9) 1.5 (0.8, 2.1) 0.9 (0.6, 1.4) 0.6 (0.6, 0.6) 1.0 (0.6, 2.1)
Change from Baseline
N 2 2 4 1 9
Mean (SD) 0.1 (0.1) -0.0 (0.1) 0.0 (0.1) -0.1 0.0 (0.1)
Median (Min, Max) 0.1 (0.0, 0.1) -0.0 (-0.1, 0.0) 0.0 (-0.1, 0.2) -0.1 (-0.1, -0.1) 0.0 (-0.1, 0.2)
95% CI for Median 1 (-0.1, 0.1)
Percentage Change
N 2 2 4 1 9
Mean (SD) 3.6 (2.6) 0.8 (6.2) 3.7 (14.0) -14.7 1.0 (10.7)
Median (Min, Max) 3.6 (1.8, 5.5) 0.8 (-3.6, 5.2) 5.1 (-12.1, 16.7) -14.7 (-14.7, -14.7) 1.8 (-14.7, 16.7)
Participant with at least one newly emergent abnormal finding
1 (50.0%) 1 (50.0%) 2 (40.0%) 0 4 (36.4%)
![Page 73: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/73.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
13
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Glucose (mg/dL)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 101.0 (22.6) 99.0 (11.3) 111.8 (30.1) 90.5 (6.4) 103.6 (22.5)
Median (Min, Max) 101.0 (85.0, 117.0) 99.0 (91.0, 107.0) 94.0 (88.0, 155.0) 90.5 (86.0, 95.0) 94.0 (85.0, 155.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 95.5 (6.4) 86.5 (4.9) 151.5 (117.8) 82.0 116.9 (79.4)
Median (Min, Max) 95.5 (91.0, 100.0) 86.5 (83.0, 90.0) 94.5 (89.0, 328.0) 82.0 (82.0, 82.0) 90.0 (82.0, 328.0)
Change from Baseline
N 2 2 4 1 9
Mean (SD) -5.5 (16.3) -12.5 (16.3) 34.3 (95.1) -13.0 9.8 (63.3)
Median (Min, Max) -5.5 (-17.0, 6.0) -12.5 (-24.0, -1.0) 3.5 (-43.0, 173.0) -13.0 (-13.0, -13.0) -1.0 (-43.0, 173.0)
95% CI for Median 1 (-24.0, 6.0)
Percentage Change
N 2 2 4 1 9
Mean (SD) -3.7 (15.3) -11.8 (15.1) 21.7 (62.4) -13.7 4.7 (42.3)
Median (Min, Max) -3.7 (-14.5, 7.1) -11.8 (-22.4, -1.1) 3.8 (-32.6, 111.6) -13.7 (-13.7, -13.7) -1.1 (-32.6, 111.6)
Participant with at least one newly emergent abnormal finding
1 (50.0%) 0 0 0 1 (9.1%)
![Page 74: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/74.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
14
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Phosphorus (mg/dL)
Pre-dose value
N 1 1 3 1 6
Mean (SD) 3.5 5.9 3.8 (0.3) 4.7 4.3 (0.9)
Median (Min, Max) 3.5 (3.5, 3.5) 5.9 (5.9, 5.9) 4.0 (3.4, 4.0) 4.7 (4.7, 4.7) 4.0 (3.4, 5.9)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 75: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/75.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
15
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Potassium (mEq/L)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 4.8 (0.6) 5.1 (1.1) 4.1 (0.6) 5.2 (0.9) 4.6 (0.8)
Median (Min, Max) 4.8 (4.4, 5.2) 5.1 (4.3, 5.9) 3.8 (3.6, 5.0) 5.2 (4.5, 5.8) 4.4 (3.6, 5.9)
Post-dose value
N 2 2 4 1 9
Mean (SD) 4.4 (0.4) 5.0 (0.4) 4.0 (0.5) 4.5 4.4 (0.5)
Median (Min, Max) 4.4 (4.1, 4.7) 5.0 (4.7, 5.2) 4.2 (3.3, 4.4) 4.5 (4.5, 4.5) 4.4 (3.3, 5.2)
Change from Baseline
N 2 2 4 1 9
Mean (SD) -0.4 (0.1) -0.2 (1.5) -0.2 (0.8) -1.3 -0.3 (0.8)
Median (Min, Max) -0.4 (-0.5, -0.3) -0.2 (-1.2, 0.9) -0.2 (-0.9, 0.6) -1.3 (-1.3, -1.3) -0.5 (-1.3, 0.9)
95% CI for Median 1 (-1.2, 0.6)
Percentage Change
N 2 2 4 1 9
Mean (SD) -8.2 (2.0) 0.3 (29.2) -2.5 (19.9) -22.4 -5.4 (17.5)
Median (Min, Max) -8.2 (-9.6, -6.8) 0.3 (-20.3, 20.9) -2.2 (-21.4, 15.8) -22.4 (-22.4, -22.4) -9.6 (-22.4, 20.9)
Participant with at least one newly emergent abnormal finding
0 0 1 (20.0%) 0 1 (9.1%)
![Page 76: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/76.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
16
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Protein, total (g/d)
Pre-dose value
N 2 1 5 2 10
Mean (SD) 7.3 (0.1) 7.0 7.2 (0.7) 7.9 (1.7) 7.3 (0.8)
Median (Min, Max) 7.3 (7.2, 7.4) 7.0 (7.0, 7.0) 7.1 (6.4, 8.3) 7.9 (6.7, 9.1) 7.2 (6.4, 9.1)
Post-dose value
N 2 2 4 1 9
Mean (SD) 7.0 (0.1) 6.4 (0.4) 6.8 (0.5) 8.4 6.9 (0.7)
Median (Min, Max) 7.0 (6.9, 7.1) 6.4 (6.1, 6.7) 6.7 (6.4, 7.5) 8.4 (8.4, 8.4) 6.8 (6.1, 8.4)
Change from Baseline
N 2 1 4 1 8
Mean (SD) -0.3 (0.0) -0.3 -0.4 (0.3) -0.7 -0.4 (0.3)
Median (Min, Max) -0.3 (-0.3, -0.3) -0.3 (-0.3, -0.3) -0.3 (-0.8, 0.0) -0.7 (-0.7, -0.7) -0.3 (-0.8, 0.0)
95% CI for Median 1 (-0.7, 0.0)
Percentage Change
N 2 1 4 1 8
Mean (SD) -4.1 (0.1) -4.3 -4.6 (3.9) -7.7 -4.8 (2.8)
Median (Min, Max) -4.1 (-4.2, -4.1) -4.3 (-4.3, -4.3) -4.3 (-9.6, 0.0) -7.7 (-7.7, -7.7) -4.3 (-9.6, 0.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 77: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/77.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
17
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Sodium (mEq/L)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 138.5 (0.7) 140.5 (2.1) 140.0 (2.7) 137.5 (2.1) 139.4 (2.3)
Median (Min, Max) 138.5 (138.0, 139.0) 140.5 (139.0, 142.0) 140.0 (137.0, 144.0) 137.5 (136.0, 139.0) 139.0 (136.0, 144.0)
Post-dose value
N 2 2 4 1 9
Mean (SD) 138.0 (2.8) 138.0 (2.8) 136.5 (3.3) 136.0 137.1 (2.6)
Median (Min, Max) 138.0 (136.0, 140.0) 138.0 (136.0, 140.0) 137.0 (132.0, 140.0) 136.0 (136.0, 136.0) 137.0 (132.0, 140.0)
Change from Baseline
N 2 2 4 1 9
Mean (SD) -0.5 (3.5) -2.5 (4.9) -2.5 (2.4) 0.0 -1.8 (2.8)
Median (Min, Max) -0.5 (-3.0, 2.0) -2.5 (-6.0, 1.0) -2.5 (-5.0, 0.0) 0.0 (0.0, 0.0) -1.0 (-6.0, 2.0)
95% CI for Median 1 (-5.0, 1.0)
Percentage Change
N 2 2 4 1 9
Mean (SD) -0.4 (2.6) -1.8 (3.5) -1.8 (1.7) 0.0 -1.3 (2.0)
Median (Min, Max) -0.4 (-2.2, 1.4) -1.8 (-4.2, 0.7) -1.8 (-3.6, 0.0) 0.0 (0.0, 0.0) -0.7 (-4.2, 1.4)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 78: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/78.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.3.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Chemistry
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
18
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Calculated eGFR (mL/min per 1.73m²)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 45.2 (9.1) 40.6 (16.1) 84.2 (20.5) 65.0 (6.3) 65.7 (24.2)
Median (Min, Max) 45.2 (38.8, 51.6) 40.6 (29.2, 52.0) 87.4 (62.5, 111.2) 65.0 (60.5, 69.4) 62.5 (29.2, 111.2)
Post-dose value
N 2 2 4 1 9
Mean (SD) 43.7 (9.9) 39.9 (13.5) 76.3 (22.5) 81.3 61.5 (24.0)
Median (Min, Max) 43.7 (36.7, 50.7) 39.9 (30.3, 49.5) 71.4 (54.7, 107.5) 81.3 (81.3, 81.3) 54.7 (30.3, 107.5)
Change from Baseline
N 2 2 4 1 9
Mean (SD) -1.5 (0.8) -0.7 (2.6) -1.1 (11.4) 11.9 0.3 (8.3)
Median (Min, Max) -1.5 (-2.0, -0.9) -0.7 (-2.6, 1.1) -2.5 (-12.5, 13.0) 11.9 (11.9, 11.9) -0.9 (-12.5, 13.0)
95% CI for Median 1 (-7.8, 11.9)
Percentage Change
N 2 2 4 1 9
Mean (SD) -3.5 (2.5) -0.6 (6.2) -2.2 (13.5) 17.2 0.0 (10.8)
Median (Min, Max) -3.5 (-5.2, -1.7) -0.6 (-4.9, 3.8) -4.2 (-14.3, 13.8) 17.2 (17.2, 17.2) -1.7 (-14.3, 17.2)
Participant with at least one newly emergent abnormal finding
1 (50.0%) 1 (50.0%) 2 (40.0%) 0 4 (36.4%)
![Page 79: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/79.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.4.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Urine Results
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Urine creatinine
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 50.8 (4.3) 205.9 128.0 (36.4) 130.8 (46.8) 58.4 (16.8) 104.8 (55.0)
Median (Min, Max) 49.2 (47.6, 55.7) 205.9 (205.9, 205.9) 120.4 (96.1, 167.6) 107.4 (89.5, 205.2) 56.0 (43.0, 76.3) 96.1 (43.0, 205.9)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 54.5 (9.4) 254.6 151.4 (49.1) 127.5 (44.6) 60.1 (12.7) 116.4 (64.6)
Median (Min, Max) 53.8 (45.5, 64.2) 254.6 (254.6, 254.6) 127.1 (119.3, 207.9) 102.5 (88.1, 180.2) 60.1 (51.1, 69.1) 98.8 (45.5, 254.6)
Change from Baseline
N 3 1 3 5 2 14
Mean (SD) 3.7 (9.8) 48.7 23.4 (16.8) -3.3 (68.9) -6.1 (27.1) 7.2 (42.9)
Median (Min, Max) -1.9 (-2.1, 15.0) 48.7 (48.7, 48.7) 23.2 (6.7, 40.3) 13.0 (-110.2, 75.9) -6.1 (-25.2, 13.1) 13.1 (-110.2, 75.9)
95% CI for Median 1 (-2.1, 40.3)
Percentage Change
N 3 1 3 5 2 14
Mean (SD) 7.6 (19.9) 23.7 17.9 (10.7) 6.4 (46.8) -4.8 (39.9) 8.7 (30.7)
Median (Min, Max) -3.4 (-4.4, 30.5) 23.7 (23.7, 23.7) 24.1 (5.6, 24.1) 14.5 (-53.7, 72.8) -4.8 (-33.0, 23.4) 15.4 (-53.7, 72.8)
Participant with at least one newly emergent abnormal finding
0 1 (100.0%) 0 0 0 1 (6.7%)
![Page 80: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/80.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.4.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Urine Results
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Microalbuminuria
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 651.9 (640.7) 4.0 73.7 (109.3) 86.4 (80.5) 496.0 (830.8) 273.4 (477.8)
Median (Min, Max) 631.0 (21.9, 1302.8) 4.0 (4.0, 4.0) 14.9 (6.4, 199.9) 96.1 (5.5, 189.9) 18.8 (14.0, 1455.3) 21.9 (4.0, 1455.3)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 408.8 (399.7) 4.0 16.4 (16.1) 34.9 (23.1) 154.4 (184.1) 125.9 (230.4)
Median (Min, Max) 373.5 (27.9, 824.9) 4.0 (4.0, 4.0) 8.1 (6.2, 35.0) 22.2 (13.6, 61.2) 154.4 (24.2, 284.6) 26.1 (4.0, 824.9)
Change from Baseline
N 3 1 3 5 2 14
Mean (SD) -243.1 (242.3) 0.0 -57.3 (93.3) -51.6 (68.3) -580.3 (835.0) -165.7 (321.1)
Median (Min, Max) -257.5 (-477.9, 6.0) 0.0 (0.0, 0.0) -8.7 (-164.9, 1.7) -34.9 (-131.1, 16.7) -580.3 (-1171, 10.2) -21.8 (-1171, 16.7)
95% CI for Median 1 (-165, 6.6)
Percentage Change
N 3 1 3 5 2 14
Mean (SD) -16.7 (38.2) 0.0 -38.1 (57.3) 41.3 (162.8) -3.8 (108.4) 2.5 (104.1)
Median (Min, Max) -36.7 (-40.8, 27.4) 0.0 (0.0, 0.0) -58.4 (-82.5, 26.6) -36.3 (-86.1, 303.6) -3.8 (-80.4, 72.9) -36.5 (-86.1, 303.6)
Participant with at least one newly emergent abnormal finding
0 0 0 1 (20.0%) 1 (33.3%) 2 (13.3%)
![Page 81: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/81.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.4.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Urine Results
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
3
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Protein
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 101.6 (79.8) 22.3 34.0 (24.7) 34.1 (19.5) 82.4 (125.1) 56.4 (65.5)
Median (Min, Max) 107.6 (18.9, 178.2) 22.3 (22.3, 22.3) 28.1 (12.8, 61.2) 29.6 (10.7, 59.7) 12.0 (8.3, 226.8) 28.1 (8.3, 226.8)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 66.9 (46.5) 21.4 26.3 (14.9) 21.7 (10.3) 40.0 (34.3) 35.0 (28.8)
Median (Min, Max) 66.7 (20.5, 113.5) 21.4 (21.4, 21.4) 21.3 (14.5, 43.0) 21.5 (9.6, 32.9) 40.0 (15.7, 64.2) 21.5 (9.6, 113.5)
Change from Baseline
N 3 1 3 5 2 14
Mean (SD) -34.7 (33.6) -0.9 -7.8 (28.6) -12.3 (16.5) -79.5 (117.6) -24.9 (45.8)
Median (Min, Max) -40.9 (-64.7, 1.6) -0.9 (-0.9, -0.9) 1.7 (-39.9, 14.9) -16.1 (-28.6, 10.0) -79.5 (-162.6, 3.7) -8.6 (-162.6, 14.9)
95% CI for Median 1 (-39.9, 3.7)
Percentage Change
N 3 1 3 5 2 14
Mean (SD) -22.0 (26.4) -4.0 0.4 (60.2) -24.7 (42.4) -20.4 (72.5) -16.7 (41.6)
Median (Min, Max) -36.3 (-38.0, 8.5) -4.0 (-4.0, -4.0) 13.3 (-65.2, 53.0) -47.9 (-54.6, 43.7) -20.4 (-71.7, 30.8) -23.3 (-71.7, 53.0)
Participant with at least one newly emergent abnormal finding
0 0 1 (33.3%) 1 (20.0%) 1 (33.3%) 3 (20.0%)
![Page 82: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/82.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.4.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Urine Results
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
4
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Albumin/creatinine ratio
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 1353.0 (1350.4) 2.0 60.7 (91.2) 79.6 (89.3) 658.6 (1081.2) 441.1 (843.1)
Median (Min, Max) 1283.0 (39.0, 2737.0) 2.0 (2.0, 2.0) 9.0 (7.0, 166.0) 47.0 (4.0, 212.0) 44.0 (24.9, 1907.0) 44.0 (2.0, 2737.0)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 815.7 (903.5) 2.0 12.7 (13.4) 31.8 (26.4) 296.0 (369.1) 231.3 (496.1)
Median (Min, Max) 582.0 (52.0, 1813.0) 2.0 (2.0, 2.0) 7.0 (3.0, 28.0) 15.0 (10.0, 64.0) 296.0 (35.0, 557.0) 31.5 (2.0, 1813.0)
Change from Baseline
N 3 1 3 5 2 14
Mean (SD) -537.3 (489.5) 0.0 -48.0 (78.0) -47.8 (82.1) -670.0 (961.7) -238.2 (432.4)
Median (Min, Max) -701.0 (-924.0, 13.0) 0.0 (0.0, 0.0) -6.0 (-138.0, 0.0) 8.0 (-155.0, 17.0) -670.0 (-1350, 10.1) -3.0 (-1350, 17.0)
95% CI for Median 1 (-155, 10.1)
Percentage Change
N 3 1 3 5 2 14
Mean (SD) -18.4 (46.0) 0.0 -49.9 (44.0) 42.0 (132.3) -15.1 (78.7) -1.8 (88.6)
Median (Min, Max) -33.8 (-54.6, 33.3) 0.0 (0.0, 0.0) -66.7 (-83.1, 0.0) 36.2 (-92.2, 225.0) -15.1 (-70.8, 40.6) -16.9 (-92.2, 225.0)
Participant with at least one newly emergent abnormal finding
0 0 0 1 (20.0%) 1 (33.3%) 2 (13.3%)
![Page 83: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/83.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.4.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Urine Results
Safety Population - IC1
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Percentage change not calculated when pre-dose value equals to 0.
5
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Protein/creatinine ratio
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 2.1 (1.7) 0.1 0.3 (0.2) 0.3 (0.2) 1.1 (1.7) 0.8 (1.2)
Median (Min, Max) 2.2 (0.3, 3.7) 0.1 (0.1, 0.1) 0.2 (0.1, 0.5) 0.3 (0.1, 0.5) 0.2 (0.0, 3.0) 0.3 (0.0, 3.7)
Post-dose value
N 3 1 3 5 2 14
Mean (SD) 1.3 (1.1) 0.1 0.2 (0.0) 0.2 (0.1) 0.8 (0.7) 0.5 (0.7)
Median (Min, Max) 1.0 (0.4, 2.5) 0.1 (0.1, 0.1) 0.2 (0.1, 0.2) 0.2 (0.1, 0.3) 0.8 (0.2, 1.3) 0.2 (0.1, 2.5)
Change from Baseline
N 3 1 3 5 2 14
Mean (SD) -0.8 (0.7) -0.0 -0.1 (0.2) -0.1 (0.2) -0.7 (1.4) -0.3 (0.6)
Median (Min, Max) -1.2 (-1.3, 0.0) -0.0 (-0.0, -0.0) -0.0 (-0.3, 0.0) 0.0 (-0.3, 0.0) -0.7 (-1.7, 0.2) -0.0 (-1.7, 0.2)
95% CI for Median 1 (-0.3, 0.0)
Percentage Change
N 3 1 3 5 1 13
Mean (SD) -24.7 (33.0) -27.3 -16.9 (45.8) -18.6 (45.2) -57.6 -23.3 (36.5)
Median (Min, Max) -33.4 (-52.5, 11.8) -27.3 (-27.3, -27.3) -7.7 (-66.7, 23.5) 10.0 (-75.0, 18.8) -57.6 (-57.6, -57.6) -27.3 (-75.0, 23.5)
Participant with at least one newly emergent abnormal finding
0 0 1 (33.3%) 1 (20.0%) 1 (33.3%) 3 (20.0%)
![Page 84: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/84.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.4.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Urine Results
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Urine creatinine
Post-dose value
N 2 2 5 1 10
Mean (SD) 89.7 (56.5) 128.1 (64.8) 78.5 (48.6) 83.5 91.1 (47.6)
Median (Min, Max) 89.7 (49.7, 129.6) 128.1 (82.3, 173.9) 73.5 (8.3, 128.1) 83.5 (83.5, 83.5) 82.9 (8.3, 173.9)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 85: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/85.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.4.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Urine Results
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Microalbuminuria
Post-dose value
N 2 2 5 1 10
Mean (SD) 66.9 (54.0) 129.8 (179.0) 118.6 (219.2) 5.0 99.1 (163.9)
Median (Min, Max) 66.9 (28.7, 105.0) 129.8 (3.2, 256.3) 13.5 (7.2, 509.4) 5.0 (5.0, 5.0) 21.1 (3.2, 509.4)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 86: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/86.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.4.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Urine Results
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
3
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Protein
Pre-dose value
N 0 1 2 0 3
Mean (SD) 100.0 10.0 (0.0) 40.0 (52.0)
Median (Min, Max) 100.0 (100.0, 100.0) 10.0 (10.0, 10.0) 10.0 (10.0, 100.0)
Post-dose value
N 2 2 5 1 10
Mean (SD) 20.0 (0.2) 52.3 (42.0) 30.5 (41.6) 13.2 31.0 (33.6)
Median (Min, Max) 20.0 (19.8, 20.1) 52.3 (22.6, 82.0) 10.0 (6.2, 104.1) 13.2 (13.2, 13.2) 20.0 (6.2, 104.1)
Change from Baseline
N 0 1 2 0 3
Mean (SD) -18.0 6.0 (8.9) -2.0 (15.2)
Median (Min, Max) -18.0 (-18.0, -18.0) 6.0 (-0.3, 12.3) -0.3 (-18.0, 12.3)
95% CI for Median 1 (-18.0, 12.3)
Percentage Change
N 0 1 2 0 3
Mean (SD) -18.0 60.0 (89.1) 34.0 (77.4)
Median (Min, Max) -18.0 (-18.0, -18.0) 60.0 (-3.0, 123.0) -3.0 (-18.0, 123.0)
Participant with at least one newly emergent abnormal finding
0 1 (50.0%) 0 0 1 (9.1%)
![Page 87: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/87.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.4.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Urine Results
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
4
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Albumin/creatinine ratio
Post-dose value
N 2 2 5 1 10
Mean (SD) 116.5 (133.6) 75.5 (101.1) 116.8 (160.5) 6.0 97.4 (126.1)
Median (Min, Max) 116.5 (22.0, 211.0) 75.5 (4.0, 147.0) 69.0 (11.0, 398.0) 6.0 (6.0, 6.0) 45.5 (4.0, 398.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 88: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/88.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.4.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Urine Results
Safety Population - IC2
Note:1 95% Non-parametric Confidence Interval for median
Baseline measurement defined as closest measurement before first dose administration. Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise).
5
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Protein/creatinine ratio
Pre-dose value
N 0 0 1 0 1
Mean (SD) 0.2 0.2
Median (Min, Max) 0.2 (0.2, 0.2) 0.2 (0.2, 0.2)
Post-dose value
N 2 2 5 1 10
Mean (SD) 0.3 (0.2) 0.4 (0.1) 0.4 (0.3) 0.2 0.4 (0.3)
Median (Min, Max) 0.3 (0.2, 0.4) 0.4 (0.3, 0.5) 0.3 (0.1, 0.8) 0.2 (0.2, 0.2) 0.3 (0.1, 0.8)
Change from Baseline
N 0 0 1 0 1
Mean (SD) 0.1 0.1
Median (Min, Max) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1)
95% CI for Median 1 (., .)
Percentage Change
N 0 0 1 0 1
Mean (SD) 50.0 50.0
Median (Min, Max) 50.0 (50.0, 50.0) 50.0 (50.0, 50.0)
Participant with at least one newly emergent abnormal finding
0 0 0 0 0
![Page 89: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/89.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.5.1 Summary of Clinical Laboratory Measurements by Enrollment Group: Iohexol GFR
Safety Population - IC1
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Iohexol Glomerular Filtration
Post-dose value
N 2 1 3 4 2 12
Mean (SD) 37.3 (5.6) 89.7 91.7 (6.4) 91.8 (21.9) 117.4 (37.2) 86.8 (30.0)
Median (Min, Max) 37.3 (33.3, 41.3) 89.7 (89.7, 89.7) 93.0 (84.8, 97.4) 85.5 (73.1, 123.0) 117.4 (91.0, 143.7) 89.6 (33.3, 143.7)
![Page 90: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/90.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.5.2 Summary of Clinical Laboratory Measurements by Enrollment Group: Iohexol GFR
Safety Population - IC2
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Iohexol Glomerular Filtration
Post-dose value
N 2 1 5 1 9
Mean (SD) 45.79 (3.49) 72.87 98.16 (10.35) 75.62 81.21 (23.68)
Median (Min, Max) 45.79 (43.32, 48.25) 72.87 (72.87, 72.87) 97.12 (86.47, 110.30) 75.62 (75.62, 75.62) 86.47 (43.32, 110.30)
![Page 91: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/91.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.6 Summary of Clinical Laboratory Measurements by Enrollment Group using Valid Pre-Lisinopril Records
Safety Population - IC2 with Valid Pre-Lisinopril Records
Note:1 95% Non-parametric Confidence Interval for median
Pre-lisinopril values are the average of the chart review records collected <=6 weeks prior to first lisinopril dose recorded on prior and concomitant medications form. Post-dose value calculated as last value while the participant was on drug.
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Creatinine (mg/dL)
Pre-Lisinopril value
N 1 2 2 0 5
Mean (SD) 1.8 1.3 (0.6) 0.7 (0.1) 1.2 (0.5)
Median (Min, Max) 1.8 (1.8, 1.8) 1.3 (0.9, 1.7) 0.7 (0.6, 0.8) 0.9 (0.6, 1.8)
Post-dose value
N 1 2 2 0 5
Mean (SD) 1.9 1.5 (0.9) 0.9 (0.1) 1.3 (0.6)
Median (Min, Max) 1.9 (1.9, 1.9) 1.5 (0.8, 2.1) 0.9 (0.8, 1.0) 1.0 (0.8, 2.1)
Change from Baseline
N 1 2 2 0 5
Mean (SD) 0.2 0.2 (0.4) 0.2 (0.0) 0.2 (0.2)
Median (Min, Max) 0.2 (0.2, 0.2) 0.2 (-0.1, 0.4) 0.2 (0.2, 0.2) 0.2 (-0.1, 0.4)
95% CI for Median 1 (-0.1, 0.4)
Percentage Change
N 1 2 2 0 5
Mean (SD) 9.7 7.7 (25.1) 25.4 (4.1) 15.2 (15.8)
Median (Min, Max) 9.7 (9.7, 9.7) 7.7 (-10.0, 25.4) 25.4 (22.5, 28.3) 22.5 (-10.0, 28.3)
![Page 92: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/92.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.6 Summary of Clinical Laboratory Measurements by Enrollment Group using Valid Pre-Lisinopril Records
Safety Population - IC2 with Valid Pre-Lisinopril Records
Note:1 95% Non-parametric Confidence Interval for median
Pre-lisinopril values are the average of the chart review records collected <=6 weeks prior to first lisinopril dose recorded on prior and concomitant medications form. Post-dose value calculated as last value while the participant was on drug.
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Potassium (mEq/L)
Pre-Lisinopril value
N 2 2 2 0 6
Mean (SD) 4.7 (0.4) 4.7 (0.2) 3.9 (0.1) 4.4 (0.5)
Median (Min, Max) 4.7 (4.4, 5.0) 4.7 (4.5, 4.8) 3.9 (3.8, 3.9) 4.5 (3.8, 5.0)
Post-dose value
N 2 2 2 0 6
Mean (SD) 4.4 (0.4) 5.0 (0.4) 3.9 (0.8) 4.4 (0.7)
Median (Min, Max) 4.4 (4.1, 4.7) 5.0 (4.7, 5.2) 3.9 (3.3, 4.4) 4.6 (3.3, 5.2)
Change from Baseline
N 2 2 2 0 6
Mean (SD) -0.3 (0.0) 0.3 (0.1) -0.0 (0.7) 0.0 (0.4)
Median (Min, Max) -0.3 (-0.3, -0.3) 0.3 (0.2, 0.4) -0.0 (-0.5, 0.5) -0.0 (-0.5, 0.5)
95% CI for Median 1 (-0.5, 0.5)
Percentage Change
N 2 2 2 0 6
Mean (SD) -5.9 (1.2) 6.4 (2.7) -0.7 (17.7) -0.1 (9.7)
Median (Min, Max) -5.9 (-6.8, -5.1) 6.4 (4.4, 8.3) -0.7 (-13.2, 11.9) -0.3 (-13.2, 11.9)
![Page 93: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/93.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.2.6 Summary of Clinical Laboratory Measurements by Enrollment Group using Valid Pre-Lisinopril Records
Safety Population - IC2 with Valid Pre-Lisinopril Records
Note:1 95% Non-parametric Confidence Interval for median
Pre-lisinopril values are the average of the chart review records collected <=6 weeks prior to first lisinopril dose recorded on prior and concomitant medications form. Post-dose value calculated as last value while the participant was on drug.
3
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Calculated eGFR (mL/min per 1.73m²)
Pre-Lisinopril value
N 1 2 2 0 5
Mean (SD) 40.3 41.3 (4.6) 89.7 (9.1) 60.4 (27.2)
Median (Min, Max) 40.3 (40.3, 40.3) 41.3 (38.0, 44.5) 89.7 (83.2, 96.1) 44.5 (38.0, 96.1)
Post-dose value
N 1 2 2 0 5
Mean (SD) 36.7 39.9 (13.5) 71.4 (4.9) 51.9 (19.3)
Median (Min, Max) 36.7 (36.7, 36.7) 39.9 (30.3, 49.5) 71.4 (67.9, 74.9) 49.5 (30.3, 74.9)
Change from Baseline
N 1 2 2 0 5
Mean (SD) -3.6 -1.4 (9.0) -18.3 (4.2) -8.6 (10.2)
Median (Min, Max) -3.6 (-3.6, -3.6) -1.4 (-7.7, 4.9) -18.3 (-21.2, -15.3) -7.7 (-21.2, 4.9)
95% CI for Median 1 (-21.2, 4.9)
Percentage Change
N 1 2 2 0 5
Mean (SD) -8.9 -4.6 (22.2) -20.2 (2.6) -11.7 (13.7)
Median (Min, Max) -8.9 (-8.9, -8.9) -4.6 (-20.3, 11.1) -20.2 (-22.1, -18.4) -18.4 (-22.1, 11.1)
![Page 94: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/94.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.1 Summary of Vital Signs by Enrollment Group
Safety Population - IC1
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Weight (kg)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 58.0 (5.4) 110.8 46.2 (5.7) 52.4 (10.7) 26.3 (6.2) 51.0 (21.2)
Median (Min, Max) 57.2 (53.0, 63.7) 110.8 (110.8, 110.8) 44.4 (41.7, 52.6) 55.1 (34.0, 60.9) 25.1 (20.8, 33.0) 53.0 (20.8, 110.8)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 57.5 (4.7) 110.3 47.2 (5.0) 51.4 (11.2) 26.4 (6.0) 50.7 (21.0)
Median (Min, Max) 55.9 (53.8, 62.7) 110.3 (110.3, 110.3) 45.4 (43.3, 52.8) 54.4 (32.6, 61.9) 25.2 (21.0, 32.9) 52.8 (21.0, 110.3)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) -0.5 (1.1) -0.5 0.9 (0.7) -1.0 (1.2) 0.1 (0.2) -0.3 (1.1)
Median (Min, Max) -1.0 (-1.3, 0.8) -0.5 (-0.5, -0.5) 1.0 (0.2, 1.6) -1.4 (-2.0, 1.0) 0.1 (-0.1, 0.2) -0.1 (-2.0, 1.6)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) -0.8 (2.0) -0.5 2.2 (1.7) -2.1 (2.4) 0.4 (0.6) -0.4 (2.3)
Median (Min, Max) -1.6 (-2.3, 1.5) -0.5 (-0.5, -0.5) 2.3 (0.4, 3.8) -3.4 (-4.1, 1.6) 0.4 (-0.3, 1.0) -0.3 (-4.1, 3.8)
![Page 95: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/95.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.1 Summary of Vital Signs by Enrollment Group
Safety Population - IC1
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Height (cm)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 148.2 (14.9) 165.5 147.0 (17.7) 149.4 (17.4) 126.7 (15.2) 145.2 (17.5)
Median (Min, Max) 151.0 (132.1, 161.5) 165.5 (165.5, 165.5) 145.0 (130.4, 165.7) 157.1 (122.0, 164.7) 125.6 (112.1, 142.4) 145.0 (112.1, 165.7)
![Page 96: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/96.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.1 Summary of Vital Signs by Enrollment Group
Safety Population - IC1
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
3
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Temperature (0c)
Pre-dose value
N 3 1 3 4 3 14
Mean (SD) 37.0 (0.5) 37.3 36.6 (0.4) 36.5 (0.5) 37.0 (0.4) 36.8 (0.5)
Median (Min, Max) 36.9 (36.6, 37.5) 37.3 (37.3, 37.3) 36.8 (36.1, 36.8) 36.3 (36.1, 37.2) 37.0 (36.7, 37.4) 36.8 (36.1, 37.5)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 37.1 (0.1) 36.6 36.7 (0.2) 36.4 (0.4) 36.6 (0.1) 36.7 (0.4)
Median (Min, Max) 37.2 (37.0, 37.2) 36.6 (36.6, 36.6) 36.8 (36.5, 36.9) 36.6 (35.7, 36.7) 36.6 (36.5, 36.7) 36.7 (35.7, 37.2)
Change from Baseline
N 3 1 3 4 3 14
Mean (SD) 0.1 (0.6) -0.7 0.2 (0.2) 0.1 (0.6) -0.4 (0.5) -0.1 (0.5)
Median (Min, Max) 0.3 (-0.5, 0.6) -0.7 (-0.7, -0.7) 0.1 (0.0, 0.4) 0.1 (-0.5, 0.6) -0.4 (-0.9, 0.0) 0.0 (-0.9, 0.6)
Percentage Change
N 3 1 3 4 3 14
Mean (SD) 0.4 (1.5) -1.9 0.5 (0.6) 0.2 (1.5) -1.2 (1.2) -0.1 (1.4)
Median (Min, Max) 0.8 (-1.3, 1.6) -1.9 (-1.9, -1.9) 0.3 (0.0, 1.1) 0.3 (-1.3, 1.7) -1.1 (-2.4, 0.0) 0.0 (-2.4, 1.7)
![Page 97: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/97.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.1 Summary of Vital Signs by Enrollment Group
Safety Population - IC1
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
4
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Systolic Blood Pressure (mm Hg)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 119.7 (5.5) 133.0 122.7 (0.6) 125.8 (9.2) 127.0 (7.8) 124.7 (7.1)
Median (Min, Max) 117.0 (116.0, 126.0) 133.0 (133.0, 133.0) 123.0 (122.0, 123.0) 126.0 (114.0, 137.0) 131.0 (118.0, 132.0) 123.0 (114.0, 137.0)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 114.7 (11.1) 127.0 116.0 (4.6) 117.0 (5.5) 115.7 (5.9) 116.7 (6.6)
Median (Min, Max) 116.0 (103.0, 125.0) 127.0 (127.0, 127.0) 117.0 (111.0, 120.0) 119.0 (110.0, 124.0) 118.0 (109.0, 120.0) 118.0 (103.0, 127.0)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) -5.0 (11.4) -6.0 -6.7 (4.0) -8.8 (11.7) -11.3 (2.1) -7.9 (8.1)
Median (Min, Max) -10.0 (-13.0, 8.0) -6.0 (-6.0, -6.0) -6.0 (-11.0, -3.0) -10.0 (-19.0, 10.0) -12.0 (-13.0, -9.0) -10.0 (-19.0, 10.0)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) -4.1 (9.6) -4.5 -5.4 (3.3) -6.5 (9.3) -8.9 (1.2) -6.2 (6.5)
Median (Min, Max) -7.9 (-11.2, 6.8) -4.5 (-4.5, -4.5) -4.9 (-9.0, -2.4) -8.3 (-14.4, 8.8) -9.1 (-9.9, -7.6) -7.9 (-14.4, 8.8)
![Page 98: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/98.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.1 Summary of Vital Signs by Enrollment Group
Safety Population - IC1
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
5
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Diastolic Blood Pressure (mm Hg)
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 76.0 (18.7) 73.0 75.3 (7.8) 75.4 (8.1) 78.3 (11.9) 75.9 (10.0)
Median (Min, Max) 82.0 (55.0, 91.0) 73.0 (73.0, 73.0) 73.0 (69.0, 84.0) 78.0 (63.0, 83.0) 82.0 (65.0, 88.0) 78.0 (55.0, 91.0)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 72.0 (3.5) 80.0 66.3 (8.6) 69.4 (13.5) 74.3 (13.4) 71.0 (10.2)
Median (Min, Max) 74.0 (68.0, 74.0) 80.0 (80.0, 80.0) 68.0 (57.0, 74.0) 69.0 (50.0, 86.0) 80.0 (59.0, 84.0) 74.0 (50.0, 86.0)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) -4.0 (20.0) 7.0 -9.0 (7.5) -6.0 (6.7) -4.0 (5.3) -4.9 (9.8)
Median (Min, Max) -14.0 (-17.0, 19.0) 7.0 (7.0, 7.0) -10.0 (-16.0, -1.0) -7.0 (-13.0, 5.0) -6.0 (-8.0, 2.0) -7.0 (-17.0, 19.0)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) -0.4 (30.3) 9.6 -11.8 (10.2) -8.6 (9.7) -5.3 (6.7) -5.7 (14.6)
Median (Min, Max) -17.1 (-18.7, 34.5) 9.6 (9.6, 9.6) -11.9 (-21.9, -1.4) -9.7 (-20.6, 6.2) -9.1 (-9.2, 2.4) -9.2 (-21.9, 34.5)
![Page 99: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/99.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.1 Summary of Vital Signs by Enrollment Group
Safety Population - IC1
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
6
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Pulse
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 87.3 (16.2) 102.0 81.7 (8.0) 88.2 (8.2) 96.7 (4.7) 89.3 (10.3)
Median (Min, Max) 90.0 (70.0, 102.0) 102.0 (102.0, 102.0) 81.0 (74.0, 90.0) 86.0 (79.0, 99.0) 95.0 (93.0, 102.0) 90.0 (70.0, 102.0)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 91.0 (6.6) 104.0 71.7 (11.9) 89.0 (9.0) 89.7 (7.5) 87.1 (11.6)
Median (Min, Max) 92.0 (84.0, 97.0) 104.0 (104.0, 104.0) 77.0 (58.0, 80.0) 92.0 (78.0, 98.0) 90.0 (82.0, 97.0) 90.0 (58.0, 104.0)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) 3.7 (9.6) 2.0 -10.0 (6.0) 0.8 (5.7) -7.0 (7.8) -2.3 (8.1)
Median (Min, Max) 2.0 (-5.0, 14.0) 2.0 (2.0, 2.0) -10.0 (-16.0, -4.0) -1.0 (-5.0, 10.0) -11.0 (-12.0, 2.0) -2.0 (-16.0, 14.0)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) 5.8 (12.8) 2.0 -12.6 (8.4) 1.0 (6.7) -7.2 (8.0) -2.3 (10.1)
Median (Min, Max) 2.2 (-4.9, 20.0) 2.0 (2.0, 2.0) -11.1 (-21.6, -4.9) -1.0 (-6.0, 11.6) -11.8 (-11.8, 2.1) -2.1 (-21.6, 20.0)
![Page 100: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/100.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.1 Summary of Vital Signs by Enrollment Group
Safety Population - IC1
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
7
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
Respiration
Pre-dose value
N 3 1 3 5 3 15
Mean (SD) 17.3 (2.3) 14.0 14.7 (1.2) 17.2 (4.1) 22.0 (2.0) 17.5 (3.7)
Median (Min, Max) 16.0 (16.0, 20.0) 14.0 (14.0, 14.0) 14.0 (14.0, 16.0) 18.0 (12.0, 22.0) 22.0 (20.0, 24.0) 16.0 (12.0, 24.0)
Post-dose value
N 3 1 3 5 3 15
Mean (SD) 19.3 (4.2) 18.0 20.7 (4.2) 17.2 (1.8) 20.0 (2.0) 18.9 (2.9)
Median (Min, Max) 18.0 (16.0, 24.0) 18.0 (18.0, 18.0) 22.0 (16.0, 24.0) 16.0 (16.0, 20.0) 20.0 (18.0, 22.0) 18.0 (16.0, 24.0)
Change from Baseline
N 3 1 3 5 3 15
Mean (SD) 2.0 (2.0) 4.0 6.0 (5.3) 0.0 (4.9) -2.0 (2.0) 1.5 (4.5)
Median (Min, Max) 2.0 (0.0, 4.0) 4.0 (4.0, 4.0) 8.0 (0.0, 10.0) 2.0 (-6.0, 6.0) -2.0 (-4.0, 0.0) 2.0 (-6.0, 10.0)
Percentage Change
N 3 1 3 5 3 15
Mean (SD) 10.8 (10.1) 28.6 42.9 (37.8) 5.6 (30.9) -8.9 (8.4) 12.7 (28.9)
Median (Min, Max) 12.5 (0.0, 20.0) 28.6 (28.6, 28.6) 57.1 (0.0, 71.4) 11.1 (-27.3, 50.0) -10.0 (-16.7, 0.0) 11.1 (-27.3, 71.4)
![Page 101: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/101.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.2 Summary of Vital Signs by Enrollment Group
Safety Population - IC2
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
1
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Weight (kg)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 77.4 (29.0) 31.2 (22.6) 53.7 (21.9) 45.7 (23.1) 52.5 (24.6)
Median (Min, Max) 77.4 (56.9, 97.9) 31.2 (15.2, 47.2) 54.0 (19.7, 75.7) 45.7 (29.4, 62.0) 54.0 (15.2, 97.9)
Post-dose value
N 2 2 5 1 10
Mean (SD) 77.1 (30.1) 30.8 (22.8) 53.4 (22.4) 29.5 51.2 (26.0)
Median (Min, Max) 77.1 (55.8, 98.3) 30.8 (14.6, 46.9) 53.3 (19.1, 76.5) 29.5 (29.5, 29.5) 50.8 (14.6, 98.3)
Change from Baseline
N 2 2 5 1 10
Mean (SD) -0.4 (1.1) -0.5 (0.2) -0.2 (0.7) 0.1 -0.3 (0.6)
Median (Min, Max) -0.4 (-1.1, 0.4) -0.5 (-0.6, -0.3) -0.6 (-0.9, 0.8) 0.1 (0.1, 0.1) -0.5 (-1.1, 0.8)
Percentage Change
N 2 2 5 1 10
Mean (SD) -0.8 (1.7) -2.3 (2.3) -0.9 (1.7) 0.3 -1.1 (1.7)
Median (Min, Max) -0.8 (-1.9, 0.4) -2.3 (-3.9, -0.6) -1.3 (-3.0, 1.1) 0.3 (0.3, 0.3) -1.0 (-3.9, 1.1)
![Page 102: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/102.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.2 Summary of Vital Signs by Enrollment Group
Safety Population - IC2
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
2
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Height (cm)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 156.0 (21.0) 126.3 (41.4) 148.2 (27.4) 143.6 (24.9) 144.8 (26.0)
Median (Min, Max) 156.0 (141.1, 170.8) 126.3 (97.0, 155.6) 151.0 (107.7, 181.5) 143.6 (126.0, 161.2) 151.0 (97.0, 181.5)
![Page 103: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/103.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.2 Summary of Vital Signs by Enrollment Group
Safety Population - IC2
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
3
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Temperature (0c)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 36.9 (0.4) 36.9 (0.6) 36.6 (0.3) 36.6 (0.2) 36.7 (0.4)
Median (Min, Max) 36.9 (36.6, 37.2) 36.9 (36.4, 37.3) 36.7 (36.2, 37.0) 36.6 (36.4, 36.7) 36.7 (36.2, 37.3)
Post-dose value
N 2 2 5 1 10
Mean (SD) 36.8 (0.4) 36.6 (0.3) 36.7 (0.2) 36.7 36.7 (0.2)
Median (Min, Max) 36.8 (36.5, 37.1) 36.6 (36.4, 36.8) 36.8 (36.4, 36.9) 36.7 (36.7, 36.7) 36.8 (36.4, 37.1)
Change from Baseline
N 2 2 5 1 10
Mean (SD) -0.1 (0.0) -0.3 (0.9) 0.1 (0.4) 0.3 0.0 (0.5)
Median (Min, Max) -0.1 (-0.1, -0.1) -0.3 (-0.9, 0.4) 0.1 (-0.4, 0.6) 0.3 (0.3, 0.3) 0.0 (-0.9, 0.6)
Percentage Change
N 2 2 5 1 10
Mean (SD) -0.3 (0.0) -0.7 (2.5) 0.4 (1.1) 0.8 0.1 (1.2)
Median (Min, Max) -0.3 (-0.3, -0.3) -0.7 (-2.4, 1.1) 0.3 (-1.1, 1.7) 0.8 (0.8, 0.8) 0.0 (-2.4, 1.7)
![Page 104: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/104.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.2 Summary of Vital Signs by Enrollment Group
Safety Population - IC2
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
4
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Systolic Blood Pressure (mm Hg)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 118.0 (12.7) 107.5 (0.7) 118.6 (13.8) 116.0 (4.2) 116.0 (10.6)
Median (Min, Max) 118.0 (109.0, 127.0) 107.5 (107.0, 108.0) 114.0 (106.0, 140.0) 116.0 (113.0, 119.0) 113.0 (106.0, 140.0)
Post-dose value
N 2 2 5 1 10
Mean (SD) 112.0 (29.7) 106.5 (3.5) 125.0 (14.0) 112.0 117.4 (16.0)
Median (Min, Max) 112.0 (91.0, 133.0) 106.5 (104.0, 109.0) 124.0 (112.0, 145.0) 112.0 (112.0, 112.0) 112.0 (91.0, 145.0)
Change from Baseline
N 2 2 5 1 10
Mean (SD) -6.0 (17.0) -1.0 (4.2) 6.4 (6.9) -1.0 1.7 (9.1)
Median (Min, Max) -6.0 (-18.0, 6.0) -1.0 (-4.0, 2.0) 5.0 (0.0, 18.0) -1.0 (-1.0, -1.0) 2.5 (-18.0, 18.0)
Percentage Change
N 2 2 5 1 10
Mean (SD) -5.9 (15.0) -0.9 (3.9) 5.6 (6.1) -0.9 1.3 (8.1)
Median (Min, Max) -5.9 (-16.5, 4.7) -0.9 (-3.7, 1.9) 3.6 (0.0, 15.8) -0.9 (-0.9, -0.9) 2.3 (-16.5, 15.8)
![Page 105: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/105.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.2 Summary of Vital Signs by Enrollment Group
Safety Population - IC2
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
5
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Diastolic Blood Pressure (mm Hg)
Pre-dose value
N 2 2 5 2 11
Mean (SD) 71.0 (7.1) 67.5 (2.1) 71.0 (16.0) 63.0 (1.4) 68.9 (10.9)
Median (Min, Max) 71.0 (66.0, 76.0) 67.5 (66.0, 69.0) 64.0 (57.0, 92.0) 63.0 (62.0, 64.0) 66.0 (57.0, 92.0)
Post-dose value
N 2 2 5 1 10
Mean (SD) 65.0 (1.4) 61.0 (11.3) 74.4 (17.9) 61.0 68.5 (14.1)
Median (Min, Max) 65.0 (64.0, 66.0) 61.0 (53.0, 69.0) 73.0 (55.0, 101.0) 61.0 (61.0, 61.0) 65.0 (53.0, 101.0)
Change from Baseline
N 2 2 5 1 10
Mean (SD) -6.0 (5.7) -6.5 (9.2) 3.4 (14.0) -3.0 -1.1 (11.1)
Median (Min, Max) -6.0 (-10.0, -2.0) -6.5 (-13.0, 0.0) 5.0 (-11.0, 23.0) -3.0 (-3.0, -3.0) -2.5 (-13.0, 23.0)
Percentage Change
N 2 2 5 1 10
Mean (SD) -8.1 (7.2) -9.9 (13.9) 6.2 (21.9) -4.7 -1.0 (17.3)
Median (Min, Max) -8.1 (-13.2, -3.0) -9.9 (-19.7, 0.0) 8.8 (-14.1, 39.7) -4.7 (-4.7, -4.7) -3.9 (-19.7, 39.7)
![Page 106: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/106.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.2 Summary of Vital Signs by Enrollment Group
Safety Population - IC2
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
6
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Pulse
Pre-dose value
N 2 2 5 2 11
Mean (SD) 85.0 (24.0) 92.5 (10.6) 88.6 (11.9) 81.5 (3.5) 87.4 (11.9)
Median (Min, Max) 85.0 (68.0, 102.0) 92.5 (85.0, 100.0) 81.0 (79.0, 104.0) 81.5 (79.0, 84.0) 84.0 (68.0, 104.0)
Post-dose value
N 2 2 5 1 10
Mean (SD) 82.5 (9.2) 93.0 (2.8) 76.4 (6.1) 72.0 80.5 (8.9)
Median (Min, Max) 82.5 (76.0, 89.0) 93.0 (91.0, 95.0) 74.0 (70.0, 86.0) 72.0 (72.0, 72.0) 77.0 (70.0, 95.0)
Change from Baseline
N 2 2 5 1 10
Mean (SD) -2.5 (14.8) 0.5 (13.4) -12.2 (14.1) -12.0 -7.7 (12.9)
Median (Min, Max) -2.5 (-13.0, 8.0) 0.5 (-9.0, 10.0) -10.0 (-30.0, 7.0) -12.0 (-12.0, -12.0) -9.5 (-30.0, 10.0)
Percentage Change
N 2 2 5 1 10
Mean (SD) -0.5 (17.3) 1.4 (14.7) -12.5 (14.3) -14.3 -7.5 (14.0)
Median (Min, Max) -0.5 (-12.7, 11.8) 1.4 (-9.0, 11.8) -12.5 (-28.8, 8.9) -14.3 (-14.3, -14.3) -10.8 (-28.8, 11.8)
![Page 107: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/107.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.3.2 Summary of Vital Signs by Enrollment Group
Safety Population - IC2
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). Trough PK visit blood pressure evaluation before the PK visit dose is used as post-dose value.
7
30 – 59 ml/min per 1.73m² >60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
Respiration
Pre-dose value
N 0 2 4 1 7
Mean (SD) 22.0 (0.0) 19.0 (4.8) 18.0 19.7 (3.7)
Median (Min, Max) 22.0 (22.0, 22.0) 21.0 (12.0, 22.0) 18.0 (18.0, 18.0) 22.0 (12.0, 22.0)
Post-dose value
N 2 2 5 1 10
Mean (SD) 18.0 (0.0) 21.0 (1.4) 18.0 (2.0) 22.0 19.0 (2.2)
Median (Min, Max) 18.0 (18.0, 18.0) 21.0 (20.0, 22.0) 18.0 (16.0, 20.0) 22.0 (22.0, 22.0) 19.0 (16.0, 22.0)
Change from Baseline
N 0 2 4 1 7
Mean (SD) -1.0 (1.4) -0.5 (5.0) 4.0 0.0 (4.0)
Median (Min, Max) -1.0 (-2.0, 0.0) -1.0 (-6.0, 6.0) 4.0 (4.0, 4.0) 0.0 (-6.0, 6.0)
Percentage Change
N 0 2 4 1 7
Mean (SD) -4.6 (6.4) 3.4 (33.1) 22.2 3.8 (25.2)
Median (Min, Max) -4.6 (-9.1, 0.0) -4.6 (-27.3, 50.0) 22.2 (22.2, 22.2) 0.0 (-27.3, 50.0)
![Page 108: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/108.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.4.1 Summary of Concomitant Medications by Drug Classification, Drug Name and Enrollment Group
Safety Population - IC1
Note: The percentages are based on the total number of enrolled participants in each treatment group or total.
Participants are counted once for each medication after the start of study dose.
1
30 – 59 ml/min per 1.73m² > 60 ml/min per 1.73m²
0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=1) 0.1 mg/kg/day
(N=3) 0.2 mg/kg/day
(N=5) 0.4 mg/kg/day
(N=3) Total
(N=15)
WHO Class Medication Name
Pts With Medn N (%)
Total Medns
N
Pts With Medn N (%)
Total Medns
N
Pts With Medn N (%)
Total Medns
N
Pts With Medn N (%)
Total Medns
N
Pts With Medn N (%)
Total Medns
N
Pts With Medn N (%)
Total Medns
N
ALIMENTARY TRACT AND METABOLISM 0 0 0 0 0 0 1 (20%) 1 1 (33.3%) 1 2 (13.3%) 2
ONDANSETRON 0 0 0 0 0 0 1 (20%) 1 0 0 1 (6.7%) 1
VITAMIN D NOS 0 0 0 0 0 0 0 0 1 (33.3%) 1 1 (6.7%) 1
CARDIOVASCULAR SYSTEM
2 (66.7%)
2
1 (100%)
1
1 (33.3%)
1
3 (60%)
3
2 (66.7%)
2
9 (60%)
9
LISINOPRIL 2 (66.7%) 2 1 (100%) 1 1 (33.3%) 1 3 (60%) 3 2 (66.7%) 2 9 (60%) 9
DERMATOLOGICALS
1 (33.3%)
1
0
0
0
0
0
0
0
0
1 (6.7%)
1
BENZOYL PEROXIDE 1 (33.3%) 1 0 0 0 0 0 0 0 0 1 (6.7%) 1
SENSORY ORGANS
0
0
0
0
0
0
1 (20%)
1
0
0
1 (6.7%)
1
CIPRO HC 0 0 0 0 0 0 1 (20%) 1 0 0 1 (6.7%) 1
![Page 109: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/109.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.4.2 Summary of Concomitant Medications by Drug Classification, Drug Name and Enrollment Group
Safety Population - IC2
Note: The percentages are based on the total number of enrolled participants in each treatment group or total.
Participants are counted once for each medication after the start of study dose.
1
30 – 59 ml/min per 1.73m² > 60 ml/min per 1.73m²
0.1 mg/kg/day
(N=2) 0.2 mg/kg/day
(N=2) 0.1 mg/kg/day
(N=5) 0.2 mg/kg/day
(N=2) Total
(N=11)
WHO Class Medication Name
Pts With Medn N (%)
Total Medns
N
Pts With Medn N (%)
Total Medns
N
Pts With Medn N (%)
Total Medns
N
Pts With Medn N (%)
Total Medns
N
Pts With Medn N (%)
Total Medns
N
ALIMENTARY TRACT AND METABOLISM 0 0 1 (50%) 1 0 0 0 0 1 (9.1%) 1
ESOMEPRAZOLE 0 0 1 (50%) 1 0 0 0 0 1 (9.1%) 1
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
1 (50%)
1
0
0
0
0
0
0
1 (9.1%)
1
MYCOPHENOLATE MOFETIL 1 (50%) 1 0 0 0 0 0 0 1 (9.1%) 1
RESPIRATORY SYSTEM
0
0
1 (50%)
1
0
0
0
0
1 (9.1%)
1
MONTELUKAST SODIUM 0 0 1 (50%) 1 0 0 0 0 1 (9.1%) 1
![Page 110: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/110.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.5.1 Summary of Physical Examination Abnormal Findings by Body System and Enrollment Group
Safety Population - IC1
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). 1
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
Timepoint
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Abnormal Findings at Baseline
Participant with at least one abnormal finding at baseline
2 (66.7%) 1 (100.0%) 0 2 (40.0%) 1 (33.3%) 6 (40.0%)
General appearance 0 0 0 0 0 0
General behavior 0 0 0 0 0 0
Skin 1 (33.3%) 1 (100.0%) 0 0 0 2 (13.3%)
Head 0 0 0 0 0 0
Eyes and vision 0 0 0 0 0 0
Ears, nose and throat 1 (33.3%) 0 0 1 (20.0%) 1 (33.3%) 3 (20.0%)
Neck/thyroid 0 0 0 0 0 0
Blood/lymphatic 0 0 0 0 0 0
Cardiovascular 0 0 0 1 (20.0%) 0 1 (6.7%)
Respiratory 0 0 0 0 0 0
Abdomen 0 0 0 1 (20.0%) 1 (33.3%) 2 (13.3%)
Nervous system 0 0 0 0 0 0
Musculoskeletal 1 (33.3%) 0 0 0 0 1 (6.7%)
Extremities 1 (33.3%) 1 (100.0%) 0 0 0 2 (13.3%)
Anorectal/genital 0 0 0 0 0 0
Edema 2 (66.7%) 1 (100.0%) 0 0 0 3 (20.0%)
![Page 111: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/111.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.5.1 Summary of Physical Examination Abnormal Findings by Body System and Enrollment Group
Safety Population - IC1
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). 2
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
Timepoint
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=1)
0.1 mg/kg/day
(N=3)
0.2 mg/kg/day
(N=5)
0.4 mg/kg/day
(N=3) Total
(N=15)
Newly Emergent Abnormal Findings After Study Drug Administration
Participant with at least one newly emergent abnormal finding
1 (33.3%) 1 (100.0%) 0 0 0 2 (13.3%)
General appearance 0 1 (100.0%) 0 0 0 1 (6.7%)
General behavior 0 0 0 0 0 0
Skin 0 0 0 0 0 0
Head 0 0 0 0 0 0
Eyes and vision 0 0 0 0 0 0
Ears, nose and throat 0 0 0 0 0 0
Neck/thyroid 0 0 0 0 0 0
Blood/lymphatic 0 0 0 0 0 0
Cardiovascular 0 0 0 0 0 0
Respiratory 0 0 0 0 0 0
Abdomen 0 0 0 0 0 0
Nervous system 0 0 0 0 0 0
Musculoskeletal 0 0 0 0 0 0
Extremities 0 0 0 0 0 0
Anorectal/genital 0 0 0 0 0 0
Edema 1 (33.3%) 0 0 0 0 1 (6.7%)
![Page 112: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/112.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.5.2 Summary of Physical Examination Abnormal Findings by Body System and Enrollment Group
Safety Population - IC2
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). 1
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
Timepoint
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Abnormal Findings at Baseline
Participant with at least one abnormal finding at baseline
0 2 (100.0%) 2 (40.0%) 1 (50.0%) 5 (45.5%)
General appearance 0 1 (50.0%) 2 (40.0%) 0 3 (27.3%)
General behavior 0 0 1 (20.0%) 0 1 (9.1%)
Skin 0 0 0 0 0
Head 0 0 1 (20.0%) 0 1 (9.1%)
Eyes and vision 0 1 (50.0%) 0 0 1 (9.1%)
Ears, nose and throat 0 0 0 0 0
Neck/thyroid 0 0 0 0 0
Blood/lymphatic 0 0 0 0 0
Cardiovascular 0 0 0 0 0
Respiratory 0 0 0 0 0
Abdomen 0 1 (50.0%) 1 (20.0%) 1 (50.0%) 3 (27.3%)
Nervous system 0 0 0 0 0
Musculoskeletal 0 0 0 0 0
Extremities 0 0 0 0 0
Anorectal/genital 0 0 0 0 0
Edema 0 0 0 0 0
![Page 113: Table 14.3.1.1.1 Summary of Adverse Events by Enrollment ......Table 14.3.1.3 Adverse Events by System Organ Class, Preferred Term, Severity and by Enrollment Group Safety Population](https://reader033.vdocuments.us/reader033/viewer/2022052011/6026fb870a61d24a481b4190/html5/thumbnails/113.jpg)
Protocol: NICHD-2011-HTN01 – HTN-Lisinopril PK Data Lock: May 5, 2014 DRAFT (v1.0) CONFIDENTIAL
Table 14.3.5.2 Summary of Physical Examination Abnormal Findings by Body System and Enrollment Group
Safety Population - IC2
Note: Baseline measurement defined as closest measurement before first dose administration.
Post-dose value calculated as last value while the participant was on study drug (PK visit if completed and interim otherwise). 2
30 – 59 ml/min per
1.73m² >60 ml/min per 1.73m²
Timepoint
0.1 mg/kg/day
(N=2)
0.2 mg/kg/day
(N=2)
0.1 mg/kg/day
(N=5)
0.2 mg/kg/day
(N=2) Total
(N=11)
Newly Emergent Abnormal Findings After Study Drug Administration
Participant with at least one newly emergent abnormal finding
2 (100.0%) 1 (50.0%) 0 0 3 (27.3%)
General appearance 1 (50.0%) 0 0 0 1 (9.1%)
General behavior 0 0 0 0 0
Skin 2 (100.0%) 1 (50.0%) 0 0 3 (27.3%)
Head 0 0 0 0 0
Eyes and vision 0 0 0 0 0
Ears, nose and throat 1 (50.0%) 0 0 0 1 (9.1%)
Neck/thyroid 0 0 0 0 0
Blood/lymphatic 0 0 0 0 0
Cardiovascular 0 0 0 0 0
Respiratory 0 0 0 0 0
Abdomen 2 (100.0%) 0 0 0 2 (18.2%)
Nervous system 0 0 0 0 0
Musculoskeletal 0 0 0 0 0
Extremities 0 0 0 0 0
Anorectal/genital 0 0 0 0 0
Edema 0 0 0 0 0